Spectrum Pharmaceuticals (SPPI) 10-Q 3 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2017	Oct. 31, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	SPPI
Entity Registrant Name	SPECTRUM PHARMACEUTICALS INC
Entity Central Index Key	831,547
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		100,662,238

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 247,468	$ 158,222
Marketable securities	248	247
Accounts receivable, net of allowance for doubtful accounts of $88 and $88, respectively	37,767	39,782
Other receivables	5,876	5,754
Inventories	8,983	8,715
Prepaid expenses and other assets	2,957	3,930
Total current assets	303,299	216,650
Property and equipment, net of accumulated depreciation	615	449
Intangible assets, net of accumulated amortization and impairment charges	144,036	164,234
Goodwill	18,131	17,886
Other assets	35,736	29,549
Total assets	501,817	428,768
Current liabilities:
Accounts payable and other accrued liabilities	49,635	52,483
Accrued payroll and benefits	7,636	8,981
Deferred revenue	2,783	3,188
FOLOTYN development liability	153	861
Total current liabilities	60,207	65,513
FOLOTYN development liability, less current portion	12,273	12,269
Deferred revenue, less current portion	324	323
Acquisition-related contingent obligations	4,551	1,315
Deferred tax liabilities	6,829	6,675
Other long-term liabilities	11,127	9,604
Convertible senior notes	101,770	97,043
Total liabilities	197,081	192,742
Commitments and contingencies
Stockholders’ equity:
Preferred stock	0	0
Common stock, $0.001 par value; 175,000,000 shares authorized; 94,061,740 and 80,466,735 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively	94	80
Additional paid-in capital	765,754	640,166
Accumulated other comprehensive income (loss)	3,673	(1,579)
Accumulated deficit	(464,785)	(402,641)
Total stockholders’ equity	304,736	236,026
Total liabilities and stockholders’ equity	501,817	428,768
Series B Junior Participating Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	0	0
Series E Convertible Voting Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	$ 0	$ 0

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Allowance for doubtful accounts receivable	$ 88	$ 88
Preferred stock, par value ($ per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value ($ per share)	$ 0.001	$ 0.001
Common stock, shares authorized	175,000,000	175,000,000
Common stock, shares issued (shares)	94,061,740	80,466,735
Common stock, shares outstanding	94,061,740	80,466,735
Series B Junior Participating Preferred Stock [Member]
Preferred stock, par value ($ per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Series E Convertible Voting Preferred Stock [Member]
Preferred stock, par value ($ per share)	$ 0.001	$ 0.001
Preferred stock, stated value ($ per share)	$ 10,000	$ 10,000
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues:
Product sales, net	$ 31,234	$ 30,272	$ 88,235	$ 96,401
License fees and service revenue	5,161	3,121	11,562	14,807
Total revenues	36,395	33,393	99,797	111,208
Operating costs and expenses:
Cost of sales (excludes amortization and impairment charges of intangible assets)	12,179	7,503	31,618	18,715
Cost of service revenue	0	2,221	4,221	5,716
Selling, general and administrative	18,880	19,465	54,595	69,047
Research and development	13,878	13,293	43,670	43,037
Amortization and impairment charges of intangible assets	6,928	6,907	20,718	19,052
Total operating costs and expenses	51,865	49,389	154,822	155,567
Loss from operations	(15,470)	(15,996)	(55,025)	(44,359)
Other (expense) income:
Interest expense, net	(2,014)	(2,373)	(6,196)	(7,087)
Change in fair value of contingent consideration related to acquisitions	(2,942)	78	(3,236)	(1,249)
Other income, net	251	372	901	990
Total other expenses	(4,705)	(1,923)	(8,531)	(7,346)
Loss before income taxes	(20,175)	(17,919)	(63,556)	(51,705)
Benefit for income taxes	1,466	464	1,412	635
Net loss	$ (18,709)	$ (17,455)	$ (62,144)	$ (51,070)
Net loss per share:
Basic and diluted ($ per share)	$ (0.22)	$ (0.22)	$ (0.78)	$ (0.73)
Weighted average shares outstanding:
Basic and diluted (shares)	83,463,153	79,303,380	80,177,370	70,437,885

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Net loss	$ (18,709)	$ (17,455)	$ (62,144)	$ (51,070)
Other comprehensive income:
Unrealized gain on available-for-sale securities, net of income tax expense of $2,068, $342, and $2,068, $872 for the three and nine months ended September 30, 2017 and 2016, respectively.	5,047	465	3,903	2,975
Foreign currency translation adjustments	405	96	1,349	254
Other comprehensive income	5,452	561	5,252	3,229
Total comprehensive loss	$ (13,257)	$ (16,894)	$ (56,892)	$ (47,841)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Statement of Comprehensive Income [Abstract]
Tax on available-for-sale securities	$ 2,068	$ 342	$ 2,068	$ 872

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Cash Flows From Operating Activities:
Net loss	$ (62,144)	$ (51,070)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	20,965	19,493
Stock-based compensation	9,654	9,754
Accretion of debt discount, recorded to interest expense on 2018 Convertible Notes (Note 14)	4,236	4,246
Amortization of deferred financing costs, recorded to interest expense on 2018 Convertible Notes (Note 14)	491	521
Bad debt recovery	0	(15)
Unrealized foreign currency exchange gain	(18)	(155)
Change in cash surrender value of corporate owned life insurance	(266)	0
Research and development expense recognized for the value of common stock issued in connection with QAPZOLA (Note 16(b)(x)) and ROLONTIS (Note 16(b)(xiii)) milestone achievements	0	2,419
Deferred tax liabilities	154	(40)
Income tax recognition on unrealized gain for available-for-sale securities	(2,068)	0
Change in fair value of contingent consideration related to the Talon and EVOMELA acquisitions (Note 9)	3,236	1,249
Changes in operating assets and liabilities:
Accounts receivable, net	2,143	(12,040)
Other receivables	(88)	5,571
Inventories	554	(6,768)
Prepaid expenses	972	804
Other assets	183	(2,095)
Accounts payable and other accrued obligations	(2,954)	(6,595)
Accrued payroll and benefits	(1,343)	(451)
FOLOTYN development liability (Note 15)	(704)	(526)
Acquisition related contingent obligations	0	(1,300)
Deferred revenue	(483)	(1,417)
Other long-term liabilities	1,523	1,321
Net cash used in operating activities	(25,957)	(37,094)
Cash Flows From Investing Activities:
Payment for corporate-owned life insurance premiums	(601)	0
Redemption of mutual funds	(1)	(1)
Purchases of property and equipment	(412)	(61)
Net cash used in investing activities	(1,014)	(62)
Cash Flows From Financing Activities:
Proceeds from exercise of stock options	3,051	190
Proceeds from sale of stock under employee stock purchase plan	406	383
Purchase and retirement of restricted stock to satisfy employees' tax liability at vesting	(1,476)	(829)
Payment of contingent consideration related to EVOMELA acquisition (Note 9(b))	0	(4,700)
Proceeds from common shares sold under an at-market-issuance sales agreement (Note 18)	113,966	73,869
Dividends paid upon conversion of Series E Convertible Voting Preferred Stock (Note 18)	0	(6)
Net cash provided by financing activities	115,947	68,907
Effect of exchange rates on cash and equivalents	270	113
Net increase in cash and cash equivalents	89,246	31,864
Cash and cash equivalents—beginning of period	158,222	139,741
Cash and cash equivalents—end of period	247,468	171,605
Supplemental disclosure of cash flow information:
Cash paid for income taxes	10	11
Cash paid for interest	$ 1,513	$ 1,650

Description of Business, Basis

Description of Business, Basis of Presentation, and Operating Segment	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Description of Business, Basis of Presentation, and Operating Segment	DESCRIPTION OF BUSINESS, BASIS OF PRESENTATION, AND OPERATING SEGMENT (a) Description of Business Spectrum Pharmaceuticals, Inc. (“Spectrum”, the “Company”, “we”, “our”, or “us”) is a biotechnology company, with a primary strategy comprised of acquiring, developing, and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. We have an in-house clinical development organization with regulatory and data management capabilities, and a commercial infrastructure and field sales force for our marketed products. Currently, we have six approved oncology/hematology products (FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA) that target different types of cancer including: non-Hodgkin's lymphoma ("NHL"), advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma ("MM"). We also have three drugs in mid-to-late stage development (in Phase 2 or Phase 3 clinical trials): • ROLONTIS (formerly referred to as SPI-2012 or LAPS-G-CSF) for chemotherapy-induced neutropenia. • QAPZOLA (formerly referred to as APAZIQUONE) for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer ("NMIBC"). • POZIOTINIB, a novel pan-HER inhibitor used in the treatment of patients with a variety of solid tumors, including breast and lung cancer. (b) Basis of Presentation Interim Financial Statements The interim financial data for the three and nine months ended September 30, 2017 and 2016 , respectively, is unaudited, and is not necessarily indicative of our operating results for a full year. In the opinion of our management, the interim data includes normal and recurring adjustments necessary for a fair presentation of our financial results for the three and nine months ended September 30, 2017 and 2016 . Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (“SEC”) rules and regulations relating to interim financial statements. The December 31, 2016 balances reported herein are derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2016 , filed with the SEC on March 14, 2017 (our "2016 Form 10-K"). The accompanying Condensed Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and Notes thereto included in our 2016 Form 10-K. Principles of Consolidation The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with GAAP and with the rules and regulations of the SEC. These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned (except for Spectrum Pharma Canada ("SPC"), as discussed below). All inter-company accounts and transactions among these legal entities have been eliminated in consolidation. Variable Interest Entity We own fifty -percent of SPC, a legal entity organized in Quebec, Canada in January 2008. Some of our clinical studies are conducted through this “variable interest entity” (as defined under applicable GAAP). We fund all of SPC’s operating costs, and since we assume all risks and rewards for this entity, we meet the GAAP criteria as being its “primary beneficiary.” Accordingly, SPC’s balance sheets and statements of operations are included in our Condensed Consolidated Financial Statements as if it were a wholly-owned subsidiary for all periods presented. (c) Operating Segment We operate in one reportable operating segment that is focused exclusively on developing and commercializing oncology and hematology drug products. For the three and nine months ended September 30, 2017 and 2016 , respectively, all of our revenue and related expenses were solely attributable to these activities. Substantially all of our assets (excluding our cash and securities held in certain foreign bank accounts and by our Ex-U.S. entities, and our ZEVALIN distribution rights for the Ex-U.S. territory) are held in the U.S.

Summary of Significant Accounti

Summary of Significant Accounting Policies and Use of Estimates	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies and Use of Estimates	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND USE OF ESTIMATES The preparation of financial statements in conformity with GAAP requires our management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. However, actual values may materially differ, since estimates are inherently uncertain. On an on-going basis, our management evaluates its estimates and assumptions, including those related to (i) gross-to-net revenue adjustments; (ii) the timing of revenue recognition; (iii) the collectability of customer accounts; (iv) whether the cost of our inventories can be recovered; (v) the fair value of our reported goodwill and intangible assets; (vi) the realization of our tax assets and estimates of our tax liabilities; (vii) the likelihood of payment and value of contingent liabilities; (viii) the fair value of our investments; (ix) the valuation of our stock options and the periodic expense recognition of stock-based compensation; and (x) the potential outcome of our ongoing or threatened litigation. The estimates and assumptions that most significantly impact the presented amounts within these Condensed Consolidated Financial Statements are further described below: (i) Revenue Recognition (a) Product Sales : We sell our products to wholesalers/distributors (i.e., our customers), except for our U.S. sales of ZEVALIN in which case the end-user (i.e., clinic or hospital) is our customer. Our wholesalers /distributors in turn sell our products directly to clinics, hospitals, and private oncology-based practices. Revenue from product sales is recognized when title and risk of loss have transferred to our customer, and the following additional criteria are met: (1) appropriate evidence of a binding arrangement exists with our customer; (2) price is substantially fixed or determinable; (3) collection from our customer is reasonably assured; (4) our customer’s obligation to pay us is not contingent on resale of the product; (5) we do not have significant continued performance obligations to our customer; and (6) we have a reasonable basis to estimate returns. Our gross revenue is reduced by our gross-to-net (“GTN”) estimates each period, resulting in our reported “product sales, net” in the accompanying Condensed Consolidated Statements of Operations. We defer revenue recognition in full if these estimates are not reasonably determinable at the time of sale. These estimates are based upon information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and their sales to end-users during the period), in combination with management’s informed judgments. Due to the inherent uncertainty of estimates, the actual amount we incur may be materially different than our GTN estimates, and require prospective revenue adjustments in periods after the initial sale was recorded. Our GTN estimates are comprised of the following categories: Product Returns Allowances : Our FUSILEV, MARQIBO, and BELEODAQ customers are permitted to return purchased product beginning at its expiration date and within six months thereafter. Our EVOMELA customers are permitted to return purchased product beginning at six months prior to its expiration date, and within 12 months thereafter (as well as for overstock inventory, as determined by end-users). Returned product is generally destroyed and not resold. Returns outside of the above-referenced criteria or for expiry of ZEVALIN and FOLOTYN are not contractually, or customarily, allowed. We estimate expected product returns for our allowance based on our historical return rates. Government Chargebacks : Our products are subject to pricing limits under certain federal government programs (e.g., Medicare and 340B Drug Pricing Program). Qualifying entities (i.e., end-users) purchase products from our customers at their qualifying discounted price. The chargeback amount we incur represents the difference between our contractual sales price to our customer, and the end-user’s applicable discounted purchase price under the government program. There may be significant lag time between our reported net product sales and our receipt of the corresponding government chargeback claims from our customers. Prompt Pay Discounts : Discounts for prompt payment are estimated at the time of sale, based on our eligible customers’ prompt payment history and the contractual discount percentage. Commercial Rebates : Commercial rebates are based on (i) our estimates of end-user purchases through a group purchasing organization ("GPO"), (ii) the corresponding contractual rebate percentage tier we expect each GPO to achieve, and (iii) our estimates of the impact of any prospective rebate program changes made by us. Medicaid Rebates : Our products are subject to state government-managed Medicaid programs, whereby rebates are issued to participating state governments. These rebates arise when a patient treated with our product is covered under Medicaid, resulting in a discounted price for our product under the applicable Medicaid program. Our Medicaid rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time lag in us receiving rebate notices from each state (generally several months or longer after our sale is recognized). Our estimates are based on our historical claim levels by state, as supplemented by management’s judgment. Distribution, Data, and GPO Administrative Fees : Distribution, data, and GPO administrative fees are paid to authorized wholesalers/distributors of our products (except for U.S. sales of ZEVALIN) for various commercial services including: contract administration, inventory management, delivery of end-user sales data, and product returns processing. These fees are based on a contractually-determined percentage of our applicable sales. (b) License Fees : Our out-license arrangements with licensees for their limited rights to market our product(s) may include one or more of the following forms of consideration: (a) upfront license fees, (b) royalties from our licensees’ sales, (c) milestone receipts from our licensees’ sales, and (d) milestone receipts upon regulatory achievements by us or our licensees. We recognize revenue from these categories based on the contractual terms that establish the legal rights and obligations between us and our licensees. We complete the following steps in determining the dollar amount and timing of revenue recognition from our license fees: (i) We first assess the number of “units of accounting” for the elements in our out-license arrangements in accordance with multiple element arrangement guidance. We consider if elements (deliverables) have standalone value, and if standalone value does not exist for a deliverable, it is combined (as applicable) with other deliverables until the "bundle" has standalone value (as a single unit of accounting). (ii) Next, we allocate arrangement consideration among the separate units of accounting (using the "relative selling price method"). (iii) Finally, we evaluate the timing of revenue recognition, which is impacted by the nature of the consideration to which we are entitled, as follows: (a) Upfront license fees : We consider whether upfront license fees are earned (i.e., realized) at the time of contract execution (i.e., when the license rights transfer to the customer) or over the actual (or implied) contractual term of the out-license. We give specific consideration to whether we have any on-going contractual service obligations to the licensee, including any requirements for us to provide on-going support services, and/or for us to supply drug products for the licensee’s future sales. As a result, we may either recognize all upfront license fees as revenue in the period of contract execution, or recognize these fees over the actual (or implied) contractual term of the out-license. (b) Royalties : We recognize revenue in the period that our licensees report product sales to us in their territory for which we are contractually entitled to a percentage-based royalty receipt (i.e., representing the period when earned and realizable). (c) Sales milestones : We recognize revenue in the period that our licensees report achievement of annual or aggregate product sales levels in their territories for which we are contractually entitled to a specified lump-sum receipt (i.e., representing the period when earned and realizable). (d) Regulatory milestones : Under the terms of the respective out-license, regulatory achievements may either be our responsibility, or that of our licensee. • When our licensee is responsible for the achievement of the regulatory milestone (and we have no on-going obligations), we recognize this revenue in the period that our product achieves specified regulatory approvals for which we are contractually entitled to a fixed receipt (i.e., representing the period when earned and realizable). • When we are responsible for the achievement of the regulatory milestone, we recognize this revenue in the period that our product achieves specified regulatory approvals for which we are contractually entitled to a fixed receipt. Regulatory approvals by governmental agencies are inherently uncertain, and require our substantial cost and effort in completing our submission for potential approval. Therefore, these regulatory milestones are “substantive” and these fixed receipts remain at-risk (i.e. unearned and unrealizable) until the period of achievement. We believe the amounts we are entitled to receive upon our achievement relates solely to our past performance and is commensurate with either (i) our performance in achieving the milestone, or (ii) the resulting enhancement in value of the drug compound. (c) Service Revenue : We receive fees under certain arrangements for (a) sales and marketing services, (b) supply chain services, (c) research and development services, and (d) clinical trial management services. Payment for these services may be triggered by (i) an established fixed-fee schedule, (ii) the completion of product delivery in our capacity as a procurement agent, (iii) the successful completion of a phase of development, (iv) favorable results from a clinical trial, and/or (v) regulatory approval events. We consider whether revenue associated with these service arrangements is “realizable and earned” each reporting period, based on our completed services or deliverables during the reporting period, and the contractual terms of the arrangement (which typically includes fee schedules). For any/all milestone achievements in the reporting period that contractually result in fixed payments due to us, we apply the “milestone method” of revenue recognition. Accordingly, this revenue recognition occurs as each “substantive” milestone (as discussed below) is achieved by us, since (1) all contingencies associated with each milestone is resolved upon its achievement, (2) the milestone achievement relates solely to our past performance, and (3) no remaining milestone performance obligations exist in relation to our receipt of payment. In recognizing revenue under the milestone method, we first assess the number of “units of accounting” in the arrangement. We consider if the separate “deliverable” has standalone value to our licensee, and if standalone value does not exist for a deliverable, it is combined with other deliverables until the "bundle" has standalone value. The allocation of arrangement consideration and the recognition of revenue is determined for those combined deliverables as a single unit of accounting. This includes allocation of consideration associated with milestones achieved by our licensees. Next, we measure and allocate arrangement consideration among the separate units of accounting. This fixed or determinable consideration is allocated to the units of accounting using the "relative selling price method". Variable fees subsequently earned (other than substantive milestone payments) are allocated to the units of accounting on the same basis. We determine whether the milestone is substantive by considering (i) the extent of our effort to achieve the milestone and/or the enhancement of the value of the delivered item(s) as a result of milestone achievement, (ii) whether the milestone achievement relates solely to our past performance, and (iii) if the milestone payment is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. For service contracts without milestones, we recognize revenue when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) services have been rendered, (iii) fees are fixed or determinable, and (iv) collectability is reasonably assured. (d) New Revenue Recognition Standard : ASU No. 2014-09 , Revenue from Contracts with Customers (Topic 606) (“ ASU 2014-09 ”), is effective for us beginning January 1, 2018. This new accounting standard requires that we recognize revenue in a manner that reasonably reflects the delivery of our goods or services to customers in return for expected consideration. To achieve this core principle, ASU 2014-09 provides the following steps in evaluating revenue arrangements: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. We are substantially complete with our evaluation of this new revenue standard, including (i) the impact on the value and timing of our revenue recognition for product sales, out-license arrangements, and service arrangements, (ii) the financial reporting transition requirements for adoption, and (iii) expanded footnote disclosures in our financial statements. We believe the adoption of ASU 2014-09 will not result in a material change of revenue recognition for our current product sales and out-license arrangements. We presently have no active service arrangements, though this new accounting standard would not have materially affected our historical revenue accounting practices for those types of arrangements. We will apply the "modified retrospective”transition method to implement ASU 2014-09 on January 1, 2018 (i.e., recognition of the cumulative effect of initially applying this standard to the opening balance of retained earnings), and as applicable, will include expanded revenue footnote disclosure requirements, beginning with our Form 10-Q for the period ended March 31, 2018. (ii) Cash and Cash Equivalents Our cash and cash equivalents consist of bank deposits and highly liquid investments with maturities of three months or less from the purchase date. (iii) Marketable Securities Our marketable securities consist of our holdings in mutual funds and bank certificates of deposit ("Bank CDs"). Since we classify these securities as “available-for-sale” under applicable GAAP, any unrealized gains or losses from their change in value is reflected in “unrealized gain on available-for-sale securities” on the accompanying Condensed Consolidated Statements of Comprehensive Loss. Realized gains and losses on available-for-sale securities are included in “other income, net” on the accompanying Condensed Consolidated Statements of Operations. (iv) Accounts Receivable, Net of Allowance for Doubtful Accounts Our accounts receivables are derived from our product sales and license fees (receivables related to our service revenue is recorded in "other receivables"), and do not bear interest. The allowance for doubtful accounts is management’s best estimate of the amount of probable credit losses in our existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted. (v) Inventories We value our inventory at the lower of (i) the actual cost of its purchase or manufacture, or (ii) its current market value. Inventory cost is determined on the first-in, first-out method. We regularly review our inventory quantities in process of manufacture and on hand. When appropriate, we record a provision for obsolete and excess inventory to derive its new cost basis, which takes into account our sales forecast by product and corresponding expiry dates of each product lot. Direct and indirect manufacturing costs related to the production of inventory prior to U.S. Food and Drug Administration ("FDA") approval are expensed through “research and development” on the accompanying Condensed Consolidated Statements of Operations, rather than being capitalized to inventory cost. (vi) Property and Equipment, Net of Accumulated Depreciation Our property and equipment is stated at historical cost, and is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. We evaluate the recoverability of “long-lived assets” (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable through on-going operations. (vii) Goodwill and Intangible Assets, Net of Accumulated Amortization and Impairment Charges Our goodwill represents the excess of our business acquisition cost over the estimated fair value of the net assets acquired in the corresponding transaction. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is evaluated for impairment on an annual basis (as of each October 1 st ), unless we identify impairment indicators that would require earlier testing. We evaluate the recoverability of indefinite-lived intangible assets at least annually, or whenever events or changes in our business indicate that an intangible asset’s (whether indefinite or definite-lived) carrying amount may not be recoverable. Such circumstances could include, but are not limited to the following: (a) a significant decrease in the market value of an asset; (b) a significant adverse change in the extent or manner in which an asset is used; or (c) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. Intangible assets with finite useful lives are amortized over their estimated useful lives on a straight-line basis. We review these assets for potential impairment if/when facts or circumstances suggest that the carrying value of these assets may not be recoverable. (viii) Stock-Based Compensation Stock-based compensation expense for equity awards granted to our employees and members of our board of directors is recognized on a straight-line basis over each award's vesting period. Recognized compensation expense is net of an estimated forfeiture rate, representing the percentage of awards that are expected to be forfeited (by termination of employment or service) prior to vesting. We use the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) which carry service conditions for vesting. We use the Monte Carlo valuation model to value equity awards (as of the date of grant) which carry combined market conditions and service conditions for vesting. The calculation of the fair value of stock options and the recognition of stock-based compensation expense requires uncertain assumptions, including (a) the pre-vesting forfeiture rates of the awards, (b) the expected term of our stock options, (c) our stock price volatility over its expected term (and that of our designated peer group with respect to certain market-based awards), and (d) the "risk-free" interest rate over the expected term. We estimate forfeiture rates based on our employees’ overall forfeiture history, which we believe will be representative of future results. We estimate the expected term of stock options granted based on our employees’ historical exercise patterns, which we believe will be representative of their future behavior. We estimate the volatility of our common stock on the date of grant based on historical volatility of our common stock for a look-back period that corresponds with the expected term. We estimate the risk-free interest rate based upon the U.S. Treasury yields in effect at award grant, for a period equaling the expected term of the stock option. (ix) Foreign Currency Translation We translate the assets and liabilities of our foreign subsidiaries that are stated in their functional currencies (i.e., local operating currencies), to U.S. dollars at the rates of exchange in effect at the reported balance sheet date. Revenues and expenses are translated using the monthly average exchange rates during the reported period. Unrealized gains and losses from the translation of our subsidiaries’ financial statements (that are initially denominated in the corresponding functional currency) are included as a separate component of “accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets. We record foreign currency transactions, when initially denominated in a currency other than the respective functional currency of our subsidiary, at the prevailing exchange rate on the date of the transaction. Resulting unrealized foreign exchange gains and losses from transactions with third parties are included in “accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets. Beginning April 1, 2015, all unrealized foreign exchange gains and losses associated with our intercompany loans are included in "accumulated other comprehensive income (loss)" in the Condensed Consolidated Balance Sheets, as these loans with our foreign subsidiaries are not expected to be settled in the "foreseeable future." (x) Basic and Diluted Net Loss per Share We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share is the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period. (xi) Income Taxes Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We have recorded a valuation allowance to reduce our deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when we were to determine that our deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase our net income in the period that such determination was made. In the event that we are assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included in “benefit for income taxes” within the Condensed Consolidated Statements of Operations in the period the notice was received. (xii) Research and Development Costs Our research and development costs are expensed as incurred, or as certain milestone payments become due, which are generally triggered by contractual clinical or regulatory events. (xiii) Fair Value Measurements We determine measurement-date fair value based on the proceeds that would be received through the sale of the asset, or that we would pay to settle or transfer the liability, in an orderly transaction between market participants. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date. Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public. Level 3: Unobservable inputs are used when little or no market data is available.

Balance Sheet Account Detail

Balance Sheet Account Detail	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Account Detail	BALANCE SHEET ACCOUNT DETAIL The composition of selected financial statement captions that comprise the accompanying Condensed Consolidated Balance Sheets are summarized below: (a) Cash and Cash Equivalents and Marketable Securities As of September 30, 2017 and December 31, 2016 , our holdings included in “cash and cash equivalents” and “marketable securities” were at major financial institutions. Our investment policy requires that investments in marketable securities be in only highly-rated instruments, which are primarily U.S. treasury bills or U.S. treasury-backed securities, and limited investments in securities of any single issuer. We maintain cash balances in excess of federally insured limits with reputable financial institutions. To a limited degree, the Federal Deposit Insurance Corporation ("FDIC") and other third parties insure these investments. However, these investments are not insured against the possibility of a complete loss of earnings or principal and are inherently subject to the credit risk related to the continued credit worthiness of the underlying issuer and general credit market risks. We manage such risks in our portfolio by investing in highly liquid, highly rated instruments, and limit investing in long-term maturity instruments. The carrying amount of our equity securities, money market funds, Bank CDs, and mutual funds approximates their fair value (utilizing Level 1 or Level 2 inputs – see Note 2(xiii) ) because of our ability to immediately convert these instruments into cash with minimal expected change in value. The following is a summary of our presented “cash and cash equivalents” and “marketable securities”: Marketable Securities Cost Gross Gross Estimated Cash and Cash Current Long September 30, 2017 Bank deposits $ 21,574 $ — $ — $ 21,574 $ 21,574 $ — $ — Money market funds 225,894 — — 225,894 225,894 — — Bank certificates of deposits 248 — — 248 — 248 — Total cash and cash equivalents and marketable securities $ 247,716 $ — $ — $ 247,716 $ 247,468 $ 248 $ — December 31, 2016 Bank deposits $ 23,915 $ — $ — $ 23,915 $ 23,915 $ — $ — Money market funds 128,563 — — 128,563 128,563 — — Bank certificates of deposits 5,991 — — 5,991 5,744 247 — Total cash and cash equivalents and marketable securities $ 158,469 $ — $ — $ 158,469 $ 158,222 $ 247 $ — As of September 30, 2017 , none of these securities had been in a continuous unrealized loss position longer than one year. (b) Property and Equipment, Net of Accumulated Depreciation “Property and equipment, net of accumulated depreciation” consist of the following: September 30, 2017 December 31, 2016 Computer hardware and software $ 2,933 $ 2,550 Laboratory equipment 622 622 Office furniture 218 211 Leasehold improvements 2,938 2,912 Property and equipment, at cost 6,711 6,295 (Less): Accumulated depreciation (6,096 ) (5,846 ) Property and equipment, net of accumulated depreciation $ 615 $ 449 Depreciation expense (included within “total operating costs and expenses” in the accompanying Condensed Consolidated Statements of Operations) for the nine months ended September 30, 2017 and 2016 , was $0.2 million and $0.4 million , respectively. New Lease Accounting Standard In February 2016, the FASB issued ASU 2016-02 , which creates Topic 842 , Leases under the FASB Accounting Standards Codification, and which will supersede Topic 840 , Leases. ASU 2016-02 is effective for us beginning January 1, 2019, and mandates a "modified retrospective" transition method. This new standard requires lease assets and lease liabilities (including for operating leases) to be presented on the balance sheet at their "gross amount" and requires additional disclosures regarding lease arrangements. We are currently assessing the impact this guidance will have on our consolidated financial statements, though we currently do not expect it to be significant. We presently do not have any capital lease arrangements, but have several operating lease agreements. These lease agreements primarily relate to our principal executive office in Henderson, Nevada and our administrative and research and development facility in Irvine, California. (c) Inventories “Inventories” consist of the following: September 30, 2017 December 31, 2016 Raw materials $ 1,683 $ 2,991 Work-in-process 7,457 7,838 Finished goods 3,439 2,305 (Less:) Non-current portion of inventories included within "other assets" * (3,596 ) (4,419 ) Inventories $ 8,983 $ 8,715 * The "non-current" portion of inventories is presented within "other assets" in the accompanying Condensed Consolidated Balance Sheets at September 30, 2017 and December 31, 2016 , respectively. This value of $3.6 million at September 30, 2017 represents product that we expect to sell beyond September 30, 2018 . (d) Prepaid Expenses and Other Assets “Prepaid expenses and other assets” consist of the following: September 30, 2017 December 31, 2016 Prepaid insurance $ 185 $ 721 Inventory other 712 1,458 Other miscellaneous prepaid operating expenses 2,060 1,751 Prepaid expenses and other assets $ 2,957 $ 3,930 (e) Other Receivables “Other receivables” consist of the following: September 30, 2017 December 31, 2016 FOLOTYN milestone for first sale in Japan (Note 16(b)(vii) ) 2,000 — CASI note - short term* 1,515 — Other miscellaneous receivables** 1,033 239 Employee receivables*** 857 — Reimbursements due from development partners for incurred research and development expenses 418 1,796 Insurance receivable 53 500 Receivable for contracted sales and marketing services ( Note 13 ) — 1,831 Income tax receivable — 1,388 Other receivables $ 5,876 $ 5,754 * This full balance was prospectively reclassified beginning March 31, 2017 to "other receivables" (presented within current assets on the accompanying Condensed Consolidated Balance Sheets) from "other assets" (presented within non-current assets) due to this note's maturity date - see Note 10 . ** As of September 30, 2017, this balance is inclusive of $0.6 million of Medicaid rebate credits to be applied against future invoices for each respective state program. *** This balance represents amounts due to us for exercises of stock options by employees. These exercises were executed by September 30, 2017, but the cash receipts did not post to our bank account until October 2017. (f) Intangible Assets and Goodwill “Intangible assets, net of accumulated amortization and impairment charges” consist of the following: September 30, 2017 Historical Accumulated Foreign Impairment Net Amount Full Remaining MARQIBO IPR&D (NHL and other novel indications) $ 17,600 $ — $ — $ — $ 17,600 n/a n/a EVOMELA distribution rights (1) 7,700 (888 ) — — 6,812 156 138 BELEODAQ distribution rights 25,000 (6,094 ) — — 18,906 160 121 MARQIBO distribution rights 26,900 (16,102 ) — — 10,798 81 30 FOLOTYN distribution rights (2) 118,400 (50,843 ) — — 67,557 152 62 ZEVALIN distribution rights – U.S. 41,900 (36,688 ) — — 5,212 123 18 ZEVALIN distribution rights – Ex-U.S. 23,490 (16,579 ) (2,763 ) — 4,148 96 30 FUSILEV distribution rights (3) 16,778 (9,618 ) — (7,160 ) — 56 0 FOLOTYN out-license (4) 27,900 (13,874 ) — (1,023 ) 13,003 110 58 Total intangible assets $ 305,668 $ (150,686 ) $ (2,763 ) $ (8,183 ) $ 144,036 (1) The FDA approval of EVOMELA in March 2016 triggered a $6 million payment due to CyDex Pharmaceuticals, Inc. (a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated ("Ligand")). This event also resulted in a reclassification of our $7.7 million "EVOMELA IPR&D" to "EVOMELA distribution rights" due to our ability to begin its commercialization with this FDA approval. Amortization commenced on April 1, 2016, in accordance with our capitalization policy for intangible assets. (2) Beginning June 2016, we adjusted the amortization period of our FOLOTYN distribution rights to November 2022 from March 2025, representing the period through which we expect to have patent protection from generic competition (see Note 16(g) ). (3) On February 20, 2015, the U.S. District Court for the District of Nevada found the patent covering FUSILEV to be invalid, which was upheld on appeal. On April 24, 2015, Sandoz Inc. began to commercialize a generic version of FUSILEV. This represented a “triggering event” under applicable GAAP in evaluating the value of our FUSILEV distribution rights as of March 31, 2015, resulting in a $7.2 million impairment charge (non-cash) in the first quarter of 2015. We accelerated amortization expense recognition in 2015 for the then remaining net book value of FUSILEV distribution rights. (4) On May 29, 2013, we amended our FOLOTYN collaboration agreement with Mundipharma International Corporation Limited ("Mundipharma"). As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and their royalty rates and milestone payments to us were modified. This constituted a change under which we originally valued the FOLOTYN out-license as part of business combination accounting, resulting in an impairment charge (non-cash) of $1.0 million in the second quarter of 2013. December 31, 2016 Historical Accumulated Foreign Impairment Net Amount MARQIBO IPR&D (NHL and other novel indications) $ 17,600 $ — $ — $ — $ 17,600 EVOMELA distribution rights 7,700 (444 ) — — 7,256 BELEODAQ distribution rights 25,000 (4,688 ) — — 20,312 MARQIBO distribution rights 26,900 (12,863 ) — — 14,037 FOLOTYN distribution rights 118,400 (41,036 ) — — 77,364 ZEVALIN distribution rights – U.S. 41,900 (34,083 ) — — 7,817 ZEVALIN distribution rights – Ex-U.S. 23,490 (13,649 ) (5,038 ) — 4,803 FUSILEV distribution rights 16,778 (9,618 ) — (7,160 ) — FOLOTYN out-license 27,900 (11,832 ) — (1,023 ) 15,045 Total intangible assets $ 305,668 $ (128,213 ) $ (5,038 ) $ (8,183 ) $ 164,234 Intangible asset amortization and impairment expense recognized during the nine months ended September 30, 2017 and 2016 was $20.7 million and $19.1 million , respectively. Estimated intangible asset amortization expense for the remainder of 2017 and the five succeeding fiscal years and thereafter is as follows: Years Ending December 31, Remainder of 2017 $ 6,930 2018 27,719 2019 25,114 2020 19,761 2021 18,266 2022 15,882 2023 and thereafter 12,764 $ 126,436 “Goodwill” is comprised of the following: September 30, 2017 December 31, 2016 Acquisition of Talon (MARQIBO rights) $ 10,526 $ 10,526 Acquisition of ZEVALIN Ex-U.S. distribution rights 2,525 2,525 Acquisition of Allos (FOLOTYN rights) 5,346 5,346 Foreign currency exchange translation effects (266 ) (511 ) Goodwill $ 18,131 $ 17,886 (g) Other Assets “Other assets” are comprised of the following: September 30, 2017 December 31, 2016 Equity securities (see Note 10 )* $ 17,751 $ 11,533 Promissory note receivable - long term (see Note 10 )** — 1,510 Research & development supplies and other 267 224 Executive officer life insurance – cash surrender value 14,122 11,863 Inventories - non-current portion 3,596 4,419 Other assets $ 35,736 $ 29,549 * These equity securities in CASI were excluded from “marketable securities” (see Note 3(a) ) due to our intent to hold them for at least one year beyond September 30, 2017 . The unrealized gain on these "available-for-sale" equity securities are recognized as an increase to "other assets" and "accumulated deficit" (as a component of "other comprehensive income") within the accompanying Condensed Consolidated Balance Sheets and totaled $3.9 million , net of income tax, for the nine months ended September 30, 2017 . Effective January 1, 2018, under the new requirements of ASU 2016-01 , Recognition and Measurement of Financial Assets and Liabilities , we will recognize our unrealized holding gains and losses on our "available-for-sale" equity securities within "other (expense) income" on the Consolidated Statement of Operations (rather than through "other comprehensive income" on the Consolidated Statements of Comprehensive Loss). ** This note was reclassified to "other receivables" from "other assets" beginning March 31, 2017 due to its March 2018 maturity date. (h) Accounts Payable and Other Accrued Liabilities “Accounts payable and other accrued liabilities” are comprised of the following : September 30, 2017 December 31, 2016 Trade accounts payable and other accrued liabilities $ 25,464 $ 30,488 Accrued rebates 8,120 8,350 Accrued product royalty 4,610 4,723 Allowance for returns 3,458 2,309 Accrued data and distribution fees 4,344 4,222 Accrued GPO administrative fees 449 384 Accrued inventory management fee 1,347 540 Allowance for chargebacks 1,843 1,467 Accounts payable and other accrued liabilities $ 49,635 $ 52,483 Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for GTN estimates (see Note 2(i) ) were as follows: Rebates and Data and Returns Balance as of December 31, 2015 $ 20,167 $ 3,386 $ 1,394 Add: provisions 98,317 14,979 2,123 (Less): credits or actual allowances (108,667 ) (13,219 ) (1,208 ) Balance as of December 31, 2016 9,817 5,146 2,309 Add: provisions 85,602 15,495 2,164 (Less): credits or actual allowances (85,456 ) (14,501 ) (1,015 ) Balance as of September 30, 2017 $ 9,963 $ 6,140 $ 3,458 (i) Deferred Revenue Deferred revenue (current and non-current) is comprised of the following: September 30, 2017 December 31, 2016 ZEVALIN out-license deferred revenue in Asia/other territories (see Note 11 ) $ — $ 1,255 EVOMELA deferred revenue* 2,731 1,887 ZEVALIN out-license in India territory (see Note 16(b)(iii) ) 376 369 Deferred revenue $ 3,107 $ 3,511 * We commercialized EVOMELA beginning in April 2016, and have deferred revenue recognition (see Note 2(i)(a) ) for any product shipped to our distributors, but not ordered and received by end-users as of September 30, 2017 and December 31, 2016 . This deferral is a result of our present inability to estimate future customer returns and rebate levels for this recently launched product. (j) Other Long-Term Liabilities "Other long-term liabilities" are comprised of the following: September 30, 2017 December 31, 2016 Accrued executive deferred compensation $ 10,250 $ 8,352 Deferred rent (non-current portion) 83 167 Clinical study holdbacks, non-current 56 47 Other tax liabilities 738 738 Royalty liability — 300 Other long-term liabilities $ 11,127 $ 9,604

Gross-to-Net Product Sales

Gross-to-Net Product Sales	9 Months Ended
	Sep. 30, 2017
Revenue, Net [Abstract]
Gross-to-Net Product Sales	GROSS-TO-NET PRODUCT SALES The below table presents a GTN product sales reconciliation for the accompanying Condensed Consolidated Statements of Operations: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Gross product sales $ 66,517 $ 61,513 $ 192,443 $ 175,963 Commercial rebates and government chargebacks (28,075 ) (26,167 ) (85,400 ) (67,389 ) Data and distribution fees, GPO fees, and inventory management fees (5,864 ) (4,234 ) (15,503 ) (10,235 ) Prompt pay discounts (455 ) (300 ) (1,143 ) (380 ) Product returns allowance (889 ) (540 ) (2,162 ) (1,558 ) Product sales, net $ 31,234 $ 30,272 $ 88,235 $ 96,401

Composition of Total Revenue

Composition of Total Revenue	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Composition of Total Revenue	COMPOSITION OF TOTAL REVENUE The below table presents our net product sales by geography for the three and nine months ended September 30, 2017 and 2016 : Three Months Ended Nine Months Ended 2017 2016 2017 2016 United States $ 29,184 93.4 % $ 29,576 97.7 % $ 82,049 93.0 % $ 93,392 96.9 % Europe 2,050 6.6 % 696 2.3 % 6,186 7.0 % 3,009 3.1 % Product sales, net $ 31,234 100.0 % $ 30,272 100.0 % $ 88,235 100.0 % $ 96,401 100.0 % The below table presents our net product sales by drug for the three and nine months ended September 30, 2017 and 2016 : Three Months Ended Nine Months Ended 2017 2016 2017 2016 FUSILEV $ 1,792 5.7 % $ 4,893 16.2 % $ 6,426 7.3 % $ 30,568 31.7 % FOLOTYN 11,576 37.1 % 11,315 37.4 % 32,031 36.3 % 35,577 36.9 % ZEVALIN 2,737 8.8 % 2,627 8.7 % 7,881 8.9 % 8,224 8.5 % MARQIBO 1,227 3.9 % 1,925 6.4 % 5,369 6.1 % 4,921 5.1 % BELEODAQ 3,399 10.9 % 3,635 12.0 % 9,666 11.0 % 10,326 10.7 % EVOMELA 10,503 33.6 % 5,877 19.4 % 26,862 30.4 % 6,785 7.0 % Product sales, net $ 31,234 100.0 % $ 30,272 100.0 % $ 88,235 100.0 % $ 96,401 100.0 % The below table presents our license fees and service revenues by source for the three and nine months ended September 30, 2017 and 2016 : Three Months Ended Nine Months Ended 2017 2016 2017 2016 Sales and marketing contracted services ( Note 13 ) $ — — % $ 2,406 77.1 % $ 4,747 41.1 % $ 6,737 45.5 % Out-license of ZEVALIN, FOLOTYN, BELEODAQ, MARQIBO: upfront cash receipt and subsequent royalties for the Canada territory ( Note 16(b)(xv) ) — — % — — % 3 — % 6,000 40.5 % Out-license of ZEVALIN: recognition of upfront cash receipt and subsequent royalties for Asia and certain other territories, excluding China ( Note 11 ) — — % 474 15.2 % 1,245 10.8 % 1,308 8.8 % Out-license of FOLOTYN in all countries except the U.S., Canada, Europe, and Turkey: royalties ( Note 15 ) 5,148 99.7 % 229 7.3 % 5,530 47.8 % 705 4.8 % Out-license of ZEVALIN: amortization of upfront cash receipt related to India territory ( Note 16(b)(iii) ) and other 13 0.3 % 12 0.4 % 37 0.3 % 57 0.4 % License fees and service revenues $ 5,161 100.0 % $ 3,121 100.0 % $ 11,562 100.0 % $ 14,807 100.0 %

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	STOCK-BASED COMPENSATION We report our stock-based compensation expense (inclusive of our incentive stock plan, employee stock purchase plan, and 401(k) contribution matching program) in the accompanying Condensed Consolidated Statements of Operations, based on the department to which the recipient belongs. Stock-based compensation expense included within “total operating costs and expenses” for the three and nine months ended September 30, 2017 and 2016 , was as follows: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Cost of sales $ 68 $ 30 $ 150 $ 84 Research and development 592 470 1,438 1,461 Selling, general and administrative 2,750 2,650 8,066 8,209 Total stock-based compensation $ 3,410 $ 3,150 $ 9,654 $ 9,754

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Net Loss Per Share	NET LOSS PER SHARE Net loss per share was computed by dividing net loss by the weighted average number of common shares outstanding for the three and nine months ended September 30, 2017 and 2016 : Three Months Ended Nine Months Ended 2017 2016 2017 2016 Net loss $ (18,709 ) $ (17,455 ) $ (62,144 ) $ (51,070 ) Weighted average shares – basic and diluted 83,463,153 79,303,380 80,177,370 70,437,885 Net loss per share – basic and diluted $ (0.22 ) $ (0.22 ) $ (0.78 ) $ (0.73 ) The below outstanding securities were excluded from the above calculation of net loss per share because their impact under the "treasury stock method" and "if-converted method" would have been anti-dilutive due to our net loss per share in the three and nine months ended September 30, 2017 and 2016 , as summarized below: Three Months Ended Nine Months Ended 2017 2016 2017 2016 2018 Convertible Notes 10,454,799 11,401,284 10,454,799 11,401,284 Common stock options 3,144,969 1,603,028 1,504,155 1,498,034 Restricted stock awards 2,025,661 2,609,533 2,025,661 2,609,533 Common stock warrants 111,441 — 32,833 1,674 Preferred stock* — — — — Total 15,736,870 15,613,845 14,017,448 15,510,525 * In June 2016, our then 20 outstanding shares of Series E convertible voting preferred stock were converted (at the election of the preferred stockholders) into an aggregate of 40,000 common shares; a $6 thousand dividend in arrears was paid upon this conversion.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The table below summarizes certain asset and liability fair values that are included within our accompanying Condensed Consolidated Balance Sheets, and their designations among three fair value measurement categories (see Note 2(xiii)) : September 30, 2017 Level 1 Level 2 Level 3 Total Assets: Bank certificates of deposits $ — $ 248 $ — $ 248 Money market funds — 225,894 — 225,894 Equity securities ( Note 10 ) 17,751 — — 17,751 Mutual funds — 58 — 58 Deferred compensation investments (life insurance cash surrender value) — 14,122 — 14,122 * $ 17,751 $ 240,322 $ — $ 258,073 Liabilities: Deferred executive compensation liability ( Note 16(f) ) $ — $ 10,250 $ — $ 10,250 * FOLOTYN development liability ( Note 15 ) — — 12,426 12,426 Talon CVR - MARQIBO ( Note 9(a) ) — — 4,489 4,489 Corixa Liability - ZEVALIN ( Note 16(b)(i) ) — — 62 62 $ — $ 10,250 $ 16,977 $ 27,227 December 31, 2016 Level 1 Level 2 Level 3 Total Assets: Bank certificates of deposits $ — $ 5,991 $ — $ 5,991 Money market funds — 128,563 — 128,563 Equity securities ( Note 10 ) 11,533 — — 11,533 Mutual funds — 56 — 56 Deferred compensation investments (life insurance cash surrender value) — 11,863 — 11,863 * $ 11,533 $ 146,473 $ — $ 158,006 Liabilities: Deferred executive compensation liability ( Note 16(f) ) $ — $ 8,352 $ — $ 8,352 * FOLOTYN development liability ( Note 15 ) — — 13,130 13,130 Talon CVR - MARQIBO ( Note 9(a) ) — — 1,253 1,253 Corixa Liability - ZEVALIN ( Note 16(b)(i) ) — — 62 62 $ — $ 8,352 $ 14,445 $ 22,797 * The reported value of "deferred compensation investments" is based on the cash surrender value of the life insurance policies, while the value of the "deferred executive compensation liability" is based on the market value of the underlying investment holdings. We did not have any transfers between "Level 1" and "Level 2" (see Note 2(xiii)) for all periods presented. The table below summarizes the 2016 and 2017 activity of our liabilities that are valued with unobservable inputs (i.e, "Level 3"): Fair Value Measurements of Balance at December 31, 2015 $ 21,352 Settlement of Ligand Contingent Consideration liability - EVOMELA (see Note 9(b) ) (6,000 ) FOLOTYN development liability (see Note 15 ) (1,556 ) Ligand Contingent Consideration fair value adjustment prior to settlement - EVOMELA (see Note 9(b) ) 773 Talon CVR fair value adjustment - MARQIBO (see Note 9(a) ) (124 ) Balance at December 31, 2016 14,445 FOLOTYN development liability (see Note 15 ) (704 ) Talon CVR fair value adjustment - MARQIBO (see Note 9(a) ) 3,236 Balance at September 30, 2017* $ 16,977 * This amount is comprised of the current and non-current portions of “FOLOTYN development liability” and the non-current portion of “acquisition-related contingent obligations” on our accompanying Condensed Consolidated Balance Sheets. Our carrying amounts of financial instruments such as cash equivalents, accounts receivable, prepaid expenses, accounts payable, and accrued liabilities, excluding acquisition-related contingent obligations, approximate their related fair values due to their short-term nature.

Business Combinations and Conti

Business Combinations and Contingent Consideration	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Business Combinations and Contingent Consideration	BUSINESS COMBINATIONS AND CONTINGENT CONSIDERATION (a) Acquisition of Talon Therapeutics, Inc. Overview of Talon Acquisition On July 17, 2013 , we purchased all of the outstanding shares of common stock of Talon Therapeutics, Inc. (“Talon”). Through the acquisition of Talon, we gained worldwide rights to MARQIBO. We accounted for this transaction as a business combination, which required that assets acquired and liabilities assumed be recognized on the balance sheet at their fair values as of the transaction date. The Talon purchase consideration was comprised of (i) an aggregate upfront cash amount of $11.3 million , (ii) issuance of 3.0 million shares of our common stock, then equivalent to $26.3 million (based on a closing price of $8.77 per share on July 17, 2013), and (iii) the issuance of contingent value rights (“Talon CVR”) initially valued at $6.5 million . The Talon CVR was valued using a valuation model that probability-weights expected outcomes (ranging from 50% to 100% ) and discounts those amounts to their present value, using an appropriate discount rate (these represent unobservable inputs and are therefore classified as Level 3 inputs – see Note 2 (xiii) ). The Talon CVR has a maximum payout of $195 million if all sales and regulatory approval milestones are achieved, as summarized below: • $5 million upon the achievement of net sales of MARQIBO in excess of $30 million in any calendar year • $10 million upon the achievement of net sales of MARQIBO in excess of $60 million in any calendar year • $25 million upon the achievement of net sales of MARQIBO in excess of $100 million in any calendar year • $50 million upon the achievement of net sales of MARQIBO in excess of $200 million in any calendar year • $100 million upon the achievement of net sales of MARQIBO in excess of $400 million in any calendar year • $5 million upon receipt of marketing authorization from the FDA regarding Menadione Topical Lotion Talon CVR Fair Value as of September 30, 2017 and December 31, 2016 The Talon CVR fair value will continue to be evaluated on a quarterly basis. Current and future changes in its fair value results from the likelihood and timing of milestone achievement and/or the corresponding discount rate applied thereon. Adjustments to Talon CVR fair value are recognized within “change in fair value of contingent consideration related to acquisitions” in the accompanying Condensed Consolidated Statements of Operations. Fair Value December 31, 2016 $ 1,253 Fair value adjustment for the nine months ended September 30, 2017 3,236 September 30, 2017 $ 4,489 (b) Acquisition of Rights to EVOMELA and Related Contingent Consideration Overview of Acquisition of Rights to EVOMELA In March 2013, we completed the acquisition of exclusive global development and commercialization rights to Captisol-enabled®, propylene glycol-free MELPHALAN (which we market as “EVOMELA”) for use as a conditioning treatment prior to autologous stem cell transplant for patients with MM. We acquired these rights from CyDex, a wholly-owned subsidiary of Ligand, for an initial license fee of $3 million , and assumed responsibility for EVOMELA's then-ongoing clinical and regulatory development program. We accounted for this transaction as a business combination, which required that assets acquired and liabilities assumed be recognized on the balance sheet at their fair values as of the transaction date. We are required to pay Ligand additional amounts up to an aggregate $60 million upon the achievement of annual net sales thresholds (exclusive of the $6 million milestone payment triggered in March 2016, as discussed below), however, we do not expect to achieve these sales thresholds based on our estimated market size for this product and our projected market share at the time of the acquisition and to date. We also must pay Ligand royalties of 20% on our net sales of EVOMELA in all territories. Our EVOMELA royalty obligation and sales-based milestones are jointly treated as part of an "executory contract" (as defined under GAAP) that is connected with an at-market supply agreement for Captisol that was executed concurrently with this acquisition (requiring the continuing involvement of CyDex). As a result, our royalty and sales-based milestone arrangements are treated as separate transactions, distinct from the consideration paid for the EVOMELA rights. Our royalty expenses are reported through “cost of sales” in our Condensed Consolidated Statements of Operations in the same period of our recognized revenue for the product sale. Consideration Transferred The acquisition-date fair value of the consideration transferred consisted of the following: Cash consideration $ 3,000 Ligand Contingent Consideration 4,700 Total purchase consideration $ 7,700 Fair Value Estimate of Asset Acquired and Liability Assumed The total purchase consideration is allocated to the acquisition of the net tangible and intangible assets based on their estimated fair values as of the transaction date. The allocation of the total purchase price to the net assets acquired is as follows: EVOMELA distribution rights $ 7,700 We estimated the fair value of the in-process research and development using the income approach. The income approach uses valuation techniques to convert future net cash flows to a single present value (discounted) amount. We applied our net cash flow projections for EVOMELA over 10 years and a discount rate of 25% , taking into account our estimates of future incremental earnings that may be achieved upon regulatory approval and commercialization of the product(s). The fair value of the Ligand Contingent Consideration liability was determined using the probability of success and the discounted cash flow method of the income approach (representing unobservable "Level 3" inputs - see Note 2(xiii) for regulatory and sales-based milestones due to Ligand upon achievement. In March 2016, the FDA approved EVOMELA, triggering a $6 million milestone payment to Ligand that was paid in April 2016. "EVOMELA IPR&D" of $7.7 million was reclassified in April 2016 to "EVOMELA distribution rights" that is reported within "Intangible assets, net of accumulated amortization and impairment charges" (see Note 3(f) ). Amortization related to this intangible asset commenced on April 1, 2016. Ligand Contingent Consideration Fair Value as of December 31, 2016 The fair value of the Ligand Contingent Consideration immediately prior to its payment was the full $6 million payment due upon EVOMELA's FDA approval. Accordingly, in the first quarter of 2016, we recorded a $0.8 million adjustment to the “change in fair value of contingent consideration related to acquisitions” in the accompanying Condensed Consolidated Statements of Operations. W e have no further contingent consideration obligations as part of this transaction. Fair Value of December 31, 2015 $ 5,227 Fair value adjustment for the three months ended March 31, 2016 773 Payment to Ligand in April 2016 for FDA approval milestone achievement (6,000 ) December 31, 2016 $ — (c) Allos Acquisition We acquired Allos Therapeutics, Inc. (“Allos”) on September 5, 2012 for cash consideration of $205.2 million and assumed FOLOTYN distribution rights (see Note 15 ). We accounted for this transaction as a business combination, which required that assets acquired and liabilities assumed be recognized on the balance sheet at their fair values as of the transaction date. We have no ongoing contingent consideration obligations from this transaction.

Out-License of Marqibo, Zevalin

Out-License of Marqibo, Zevalin, and Evomela in China Territory	9 Months Ended
	Sep. 30, 2017
Other Commitments [Abstract]
Out-License of Marqibo, Zevalin, and Evomela in Chain Territory	OUT-LICENSE OF MARQIBO, ZEVALIN, AND EVOMELA IN CHINA TERRITORY Overview of CASI Out-License On September 17, 2014, we executed three product out-license agreements with a perpetual term (collectively, the “CASI Out-License”) with CASI Pharmaceuticals, Inc. (“CASI”), a publicly-traded biopharmaceutical company (NASDAQ: CASI) with a primary focus on the China market. Under the CASI Out-License, we granted CASI the exclusive rights to distribute two of our commercialized oncology drugs, ZEVALIN and MARQIBO, and our Phase 3 drug candidate, EVOMELA (“CASI Out-Licensed Products”) in greater China (which includes Taiwan, Hong Kong and Macau). In return, we received CASI equity for the rights related to ZEVALIN and EVOMELA and a secured promissory note for the rights related to MARQIBO. Additionally, under certain conditions which generally expire on September 17, 2019, we have a right to receive additional CASI common stock in order to maintain our post-investment ownership percentage if CASI issues additional securities. In 2016, we acquired an additional 4.6 million common shares of CASI at par value, resulting in our total holding of 10.0 million common shares as of September 30, 2017 . CASI will be responsible for the development and commercialization of these three drugs, including the submission of import drug registration applications to regulatory authorities and conducting any confirmatory clinical studies in greater China. We will provide CASI with future commercial supply of the CASI Out-Licensed Products under typical market terms. Proceeds Received in the Third Quarter of 2014 The proceeds we received, and its fair value on the CASI Out-License execution date, consisted of the following: CASI common stock (5.4 million shares) $ 8,649 (a) CASI secured promissory note due March 17, 2018, net of fair value discount ($1.5 million face value and 0.5% annual coupon) 1,310 (b) Total consideration received, net of fair value discount $ 9,959 (c) (a) Value determined based on the September 17, 2014 closing price of 5.4 million shares of CASI common stock on the NASDAQ Capital Market of $1.60 per share. Our current intention is to hold these securities on a long-term basis. Accordingly, we have presented its value of $17.8 million as of September 30, 2017 within "other assets" (rather than "marketable securities") on our accompanying Condensed Consolidated Balance Sheets. The change in fair value of these securities is reported within "other assets" and "accumulated deficit" (as a component of "other comprehensive income (loss)") within the accompanying Condensed Consolidated Balance Sheets (see Note 3(g) ). (b) Value estimated using the terms of the $1.5 million promissory note, the application of a synthetic debt rating based on CASI’s publicly-available financial information, and the prevailing interest yields on similar public debt securities as of September 17, 2014. This full balance was prospectively reclassified beginning March 31, 2017 to "other receivables" (presented within current assets on the accompanying Condensed Consolidated Balance Sheets) from "other assets" (presented within non-current assets) due to this note's maturity date of March 17, 2018 (i.e., within 12 months of March 31, 2017). (c) Presented within “license fees and service revenue” in the Consolidated Statements of Operations for the year ended December 31, 2015 (see below). In addition, CASI will be responsible for paying any royalties or milestones that we are obligated to pay to our third-party licensors resulting from the achievement of certain milestones and/or sales of CASI Out-Licensed Products, but only to the extent of the greater China portion of such royalties or milestones. License Fee Revenue Recognized in the Second Quarter of 2015 The $9.7 million value of the upfront proceeds (undiscounted, and net of certain foreign exchange adjustments) from CASI were recognized in 2015 within “license fees and service revenue” on our Consolidated Statements of Operations. The timing of this revenue recognition corresponds with the execution of supply agreements with CASI for ZEVALIN, MARQIBO, and EVOMELA. These agreements allow CASI to procure CASI Out-Licensed Products directly from approved third parties, and in such case, do not require our future involvement for their commercial supply.

Out-License Of Zevalin In Certa

Out-License Of Zevalin In Certain Ex-U.S. Territories	9 Months Ended
	Sep. 30, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Out-License Of Zevalin In Certain Ex-U.S. Territories	OUT-LICENSE OF MARQIBO, ZEVALIN, AND EVOMELA IN CHINA TERRITORY Overview of CASI Out-License On September 17, 2014, we executed three product out-license agreements with a perpetual term (collectively, the “CASI Out-License”) with CASI Pharmaceuticals, Inc. (“CASI”), a publicly-traded biopharmaceutical company (NASDAQ: CASI) with a primary focus on the China market. Under the CASI Out-License, we granted CASI the exclusive rights to distribute two of our commercialized oncology drugs, ZEVALIN and MARQIBO, and our Phase 3 drug candidate, EVOMELA (“CASI Out-Licensed Products”) in greater China (which includes Taiwan, Hong Kong and Macau). In return, we received CASI equity for the rights related to ZEVALIN and EVOMELA and a secured promissory note for the rights related to MARQIBO. Additionally, under certain conditions which generally expire on September 17, 2019, we have a right to receive additional CASI common stock in order to maintain our post-investment ownership percentage if CASI issues additional securities. In 2016, we acquired an additional 4.6 million common shares of CASI at par value, resulting in our total holding of 10.0 million common shares as of September 30, 2017 . CASI will be responsible for the development and commercialization of these three drugs, including the submission of import drug registration applications to regulatory authorities and conducting any confirmatory clinical studies in greater China. We will provide CASI with future commercial supply of the CASI Out-Licensed Products under typical market terms. Proceeds Received in the Third Quarter of 2014 The proceeds we received, and its fair value on the CASI Out-License execution date, consisted of the following: CASI common stock (5.4 million shares) $ 8,649 (a) CASI secured promissory note due March 17, 2018, net of fair value discount ($1.5 million face value and 0.5% annual coupon) 1,310 (b) Total consideration received, net of fair value discount $ 9,959 (c) (a) Value determined based on the September 17, 2014 closing price of 5.4 million shares of CASI common stock on the NASDAQ Capital Market of $1.60 per share. Our current intention is to hold these securities on a long-term basis. Accordingly, we have presented its value of $17.8 million as of September 30, 2017 within "other assets" (rather than "marketable securities") on our accompanying Condensed Consolidated Balance Sheets. The change in fair value of these securities is reported within "other assets" and "accumulated deficit" (as a component of "other comprehensive income (loss)") within the accompanying Condensed Consolidated Balance Sheets (see Note 3(g) ). (b) Value estimated using the terms of the $1.5 million promissory note, the application of a synthetic debt rating based on CASI’s publicly-available financial information, and the prevailing interest yields on similar public debt securities as of September 17, 2014. This full balance was prospectively reclassified beginning March 31, 2017 to "other receivables" (presented within current assets on the accompanying Condensed Consolidated Balance Sheets) from "other assets" (presented within non-current assets) due to this note's maturity date of March 17, 2018 (i.e., within 12 months of March 31, 2017). (c) Presented within “license fees and service revenue” in the Consolidated Statements of Operations for the year ended December 31, 2015 (see below). In addition, CASI will be responsible for paying any royalties or milestones that we are obligated to pay to our third-party licensors resulting from the achievement of certain milestones and/or sales of CASI Out-Licensed Products, but only to the extent of the greater China portion of such royalties or milestones. License Fee Revenue Recognized in the Second Quarter of 2015 The $9.7 million value of the upfront proceeds (undiscounted, and net of certain foreign exchange adjustments) from CASI were recognized in 2015 within “license fees and service revenue” on our Consolidated Statements of Operations. The timing of this revenue recognition corresponds with the execution of supply agreements with CASI for ZEVALIN, MARQIBO, and EVOMELA. These agreements allow CASI to procure CASI Out-Licensed Products directly from approved third parties, and in such case, do not require our future involvement for their commercial supply.
Mundipharma [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Out-License Of Zevalin In Certain Ex-U.S. Territories	OUT-LICENSE OF ZEVALIN IN CERTAIN EX-U.S. TERRITORIES On November 16, 2015, we entered into an out-license agreement with Mundipharma for their commercialization of ZEVALIN in Asia (excluding India and Greater China), Australia, New Zealand, Africa, the Middle East, and Latin America (including the Caribbean islands). In return, we received $18 million (comprised of $15 million received in December 2015 and $3 million received in January 2016). Of these proceeds, $15 million was recognized within "license fees and service revenue" in the fourth quarter of 2015. Of the $3 million received in January 2016, $0.5 million was recognized for the three months ended September 30, 2016, and $1.2 million and $1.3 million was recognized in the same caption for the nine months ended September 30, 2017 and 2016, respectively (this $3 million was recognized in full by June 30, 2017). Mundipharma is required to reimburse us for our payment of royalties due to Bayer Pharma AG ("Bayer") from their ZEVALIN sales (see Note 16(b)(ii)) . We are also eligible to receive an additional $2 million upon Mundipharma's achievement of a specified sales milestone, that if/when achieved, will also be reported within "license fees and service revenue".

Out-License of Zevalin, Folotyn

Out-License of Zevalin, Folotyn, Beleodaq, And Marqibo In Canada Territory	9 Months Ended
	Sep. 30, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Out-License Of Zevalin, Folotyn, Beleodaq, and Marqibo In Canada Territory	OUT-LICENSE OF MARQIBO, ZEVALIN, AND EVOMELA IN CHINA TERRITORY Overview of CASI Out-License On September 17, 2014, we executed three product out-license agreements with a perpetual term (collectively, the “CASI Out-License”) with CASI Pharmaceuticals, Inc. (“CASI”), a publicly-traded biopharmaceutical company (NASDAQ: CASI) with a primary focus on the China market. Under the CASI Out-License, we granted CASI the exclusive rights to distribute two of our commercialized oncology drugs, ZEVALIN and MARQIBO, and our Phase 3 drug candidate, EVOMELA (“CASI Out-Licensed Products”) in greater China (which includes Taiwan, Hong Kong and Macau). In return, we received CASI equity for the rights related to ZEVALIN and EVOMELA and a secured promissory note for the rights related to MARQIBO. Additionally, under certain conditions which generally expire on September 17, 2019, we have a right to receive additional CASI common stock in order to maintain our post-investment ownership percentage if CASI issues additional securities. In 2016, we acquired an additional 4.6 million common shares of CASI at par value, resulting in our total holding of 10.0 million common shares as of September 30, 2017 . CASI will be responsible for the development and commercialization of these three drugs, including the submission of import drug registration applications to regulatory authorities and conducting any confirmatory clinical studies in greater China. We will provide CASI with future commercial supply of the CASI Out-Licensed Products under typical market terms. Proceeds Received in the Third Quarter of 2014 The proceeds we received, and its fair value on the CASI Out-License execution date, consisted of the following: CASI common stock (5.4 million shares) $ 8,649 (a) CASI secured promissory note due March 17, 2018, net of fair value discount ($1.5 million face value and 0.5% annual coupon) 1,310 (b) Total consideration received, net of fair value discount $ 9,959 (c) (a) Value determined based on the September 17, 2014 closing price of 5.4 million shares of CASI common stock on the NASDAQ Capital Market of $1.60 per share. Our current intention is to hold these securities on a long-term basis. Accordingly, we have presented its value of $17.8 million as of September 30, 2017 within "other assets" (rather than "marketable securities") on our accompanying Condensed Consolidated Balance Sheets. The change in fair value of these securities is reported within "other assets" and "accumulated deficit" (as a component of "other comprehensive income (loss)") within the accompanying Condensed Consolidated Balance Sheets (see Note 3(g) ). (b) Value estimated using the terms of the $1.5 million promissory note, the application of a synthetic debt rating based on CASI’s publicly-available financial information, and the prevailing interest yields on similar public debt securities as of September 17, 2014. This full balance was prospectively reclassified beginning March 31, 2017 to "other receivables" (presented within current assets on the accompanying Condensed Consolidated Balance Sheets) from "other assets" (presented within non-current assets) due to this note's maturity date of March 17, 2018 (i.e., within 12 months of March 31, 2017). (c) Presented within “license fees and service revenue” in the Consolidated Statements of Operations for the year ended December 31, 2015 (see below). In addition, CASI will be responsible for paying any royalties or milestones that we are obligated to pay to our third-party licensors resulting from the achievement of certain milestones and/or sales of CASI Out-Licensed Products, but only to the extent of the greater China portion of such royalties or milestones. License Fee Revenue Recognized in the Second Quarter of 2015 The $9.7 million value of the upfront proceeds (undiscounted, and net of certain foreign exchange adjustments) from CASI were recognized in 2015 within “license fees and service revenue” on our Consolidated Statements of Operations. The timing of this revenue recognition corresponds with the execution of supply agreements with CASI for ZEVALIN, MARQIBO, and EVOMELA. These agreements allow CASI to procure CASI Out-Licensed Products directly from approved third parties, and in such case, do not require our future involvement for their commercial supply.
Servier Canada [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Out-License Of Zevalin, Folotyn, Beleodaq, and Marqibo In Canada Territory	OUT-LICENSE OF ZEVALIN, FOLOTYN, BELEODAQ, AND MARQIBO IN CANADA TERRITORY On January 8, 2016, we entered into a strategic partnership with Servier Canada, Inc. ("Servier") for the out-licenses of ZEVALIN, FOLOTYN, BELEODAQ, and MARQIBO. We received $6 million in upfront payments in the first quarter of 2016 which was recognized within "license fees and service revenue" in the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2016 . We will also receive development milestone payments if/when achieved, and a high single-digit royalty on their sales of these products.

Co-Promotion Arrangement With E

Co-Promotion Arrangement With Eagle Pharmaceuticals	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Co-Promotion Arrangement With Eagle Pharmaceuticals	CO-PROMOTION ARRANGEMENT WITH EAGLE PHARMACEUTICALS On November 4, 2015, we executed an agreement with Eagle Pharmaceuticals, Inc. ("Eagle") whereby designated members of our sales force concurrently marketed up to six of Eagle's products along with our products in return for fixed monthly payments (aggregating $12.8 million ), as well as variable sales-based milestones, over an 18 month contract term of January 1, 2016 through June 30, 2017 (the "Eagle Agreement"). As of July 1, 2017, our sales force is no longer marketing Eagle products, as the Eagle Agreement expired under its terms. The fixed receipts from Eagle for our sales activities, as well as reimbursements of third-party marketing services, are recognized within "license fees and service revenue" on our accompanying Condensed Consolidated Statements of Operations. This amount was $0 , $2.4 million , $4.7 million , and $6.7 million for the three and nine months ended September 30, 2017 and 2016 , respectively. No sales-based milestones were achieved in the current or prior periods. An allocation of our sales personnel costs that were dedicated to Eagle are reported within "cost of service revenue" on our accompanying Condensed Consolidated Statements of Operations, as are the reimbursable costs for third-party marketing services. These were an aggregate $0 , $2.2 million , $4.2 million , and $5.7 million for the three and nine months ended September 30, 2017 and 2016 , respectively.

Convertible Senior Notes

Convertible Senior Notes	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Convertible Senior Notes	CONVERTIBLE SENIOR NOTES Overview On December 17, 2013, we entered into an agreement for the sale of $120 million aggregate principal amount of 2.75% Convertible Senior Notes (equaling 120,000 notes, denominated in $1,000 principal units) due December 2018 (the “2018 Convertible Notes”). The 2018 Convertible Notes are convertible into shares of our common stock at a conversion rate of 95 shares per $1,000 principal units, then equating to 11.4 million common shares if fully converted. The in-the-money conversion price is equivalent to $10.53 per common share. The conversion rate and conversion price is subject to adjustment under certain limited circumstances. The 2018 Convertible Notes bear interest at a rate of 2.75% per year, payable semiannually in arrears on June 15 and December 15 of each year. The 2018 Convertible Notes will mature and become payable on December 15, 2018, subject to earlier conversion into common stock at the holders’ option. The sale of the 2018 Convertible Notes closed on December 23, 2013 and our net proceeds were $115.4 million , after deducting banker and professional fees of $4.6 million . We used a portion of these net proceeds to simultaneously enter into “bought call” and “sold warrant” transactions with Royal Bank of Canada (collectively, the “Note Hedge”). We recorded the Note Hedge on a net cost basis of $13.1 million , as a reduction to “additional paid-in capital” in our accompanying Condensed Consolidated Balance Sheets. Under applicable GAAP, the Note Hedge has not been (and is not expected to be) marked-to-market through earnings or comprehensive income. Open Market Purchases of 2018 Convertible Notes and Conversion Hedge Unwind in December 2016 In December 2016, we completed two open market purchases of our 2018 Convertible Notes, aggregating 9,963 note units (equivalent to $10 million principal value) for $9.0 million . We recognized an aggregate loss of $25,000 on the retirement of these 2018 Convertible Notes (based on its carrying value under GAAP), which is included in "other income (expense), net" on the Consolidated Statements of Operations for the year ended December 31, 2016. Accordingly, as of September 30, 2017 , $110 million in principal of our 2018 Convertible Notes remained outstanding. With these two open market purchases in December 2016, we concurrently unwound a portion of our previously sold warrants and previously purchased call options (that were part of our "conversion hedge" - see below) for aggregate net proceeds of $21,000 . We recorded a corresponding net increase to "additional paid-in capital" in the Condensed Consolidated Balance Sheets as of December 31, 2016. Conversion Hedge We entered into the Note Hedge in December 2013 to reduce the potential dilution to our stockholders and/or offset any cash payments that we are required to make in excess of the principal amount, upon conversion of the 2018 Convertible Notes (in the event that the market price of our common stock is greater than the conversion price). The strike price of the “bought call” is equal to the conversion price and conversion rate of the 2018 Convertible Notes (then matching the 11.4 million common shares the 2018 Convertible Notes may be converted into); the strike price of our “sold warrant” is $14.03 per share of our common stock, and is also for 11.4 million common shares (reduced by the partial unwinding of these instruments, as discussed above). Conversion Events On and after June 15, 2018, and until the close of business on the second scheduled trading day immediately preceding the maturity date, holders may convert all or a portion of their 2018 Convertible Notes. Prior to June 15, 2018, holders may convert all or a portion of their 2018 Convertible Notes only under any of the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter), if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than or equal to 130% of the Notes' conversion price on such trading day; (2) during the five consecutive business day period immediately following any five consecutive trading day period in which, for each trading day of that measurement period, the trading price per $1,000 principal amount of 2018 Convertible Notes for such trading day was less than 98% of the product of (i) the last reported sale price of our common stock on such trading day and (ii) the applicable conversion rate on such trading day; (3) upon the occurrence of certain corporate transactions; and (4) at any time prior to our stockholders’ approval to settle the 2018 Convertible Notes in our common shares and/or cash. As of September 30, 2017 , the 2018 Convertible Notes are not eligible to be converted into our common stock as none of the above elements (1) through (4) were met. Our stockholders’ approval of "flexible settlement" occurred at our Annual Meeting of Stockholders on June 29, 2015. As a result, we may (at our election) settle any future conversions of the 2018 Convertible Notes by paying or delivering cash, shares of our common stock, or a combination of cash and shares of our common stock. However, if the holders of the Convertible Notes do not elect any conversion into our common stock, our December 2018 obligation to repay the then-outstanding amount in cash, plus any accrued and unpaid interest, is unchanged. Carrying Value and Fair Value The carrying value of the 2018 Convertible Notes as of September 30, 2017 and December 31, 2016 , is summarized as follows: September 30, 2017 December 31, 2016 Principal amount $ 110,037 $ 110,037 (Less): Unamortized debt discount (amortized through December 2018) (7,410 ) (11,646 ) (Less): Debt issuance costs (857 ) (1,348 ) Carrying value $ 101,770 $ 97,043 As of September 30, 2017 and December 31, 2016 , the estimated aggregate fair value of the 2018 Notes is $156.4 million and $101.8 million , respectively. These estimated fair values represent a Level 2 measurement (see Note 2(xiii) ), based upon the 2018 Convertible Notes' quoted bid price at each date in a thinly-traded market. Components of Interest Expense on 2018 Convertible Notes The following table sets forth the components of interest expense recognized in the accompanying Condensed Consolidated Statements of Operations for the 2018 Convertible Notes for the nine months ended September 30, 2017 and 2016 : Nine Months Ended 2017 2016 Contractual coupon interest expense $ 2,270 $ 2,475 Amortization of debt issuance costs 491 521 Accretion of debt discount 4,236 4,246 Total $ 6,997 $ 7,242 Effective interest rate 8.65 % 8.66 %

FOLOTYN License Agreement And D

FOLOTYN License Agreement And Development Liability	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
FOLOTYN License Agreement And Development Liability	FOLOTYN LICENSE AGREEMENT AND DEVELOPMENT LIABILITY As a result of our acquisition of Allos on September 5, 2012 (see Note 9(c) ), we assumed a strategic collaboration agreement with Mundipharma (the “Mundipharma Collaboration Agreement”), as well as certain FOLOTYN clinical development obligations (the "FOLOTYN Development Liability"). Mundipharma Collaboration Agreement Summary Under the Mundipharma Collaboration Agreement, we retained full commercialization rights for FOLOTYN in the U.S. and Canada, with Mundipharma having exclusive rights to commercialize FOLOTYN in all other countries in the world (the “Mundipharma Territories”). On May 29, 2013, the Mundipharma Collaboration Agreement was amended and restated (the “Amended Mundipharma Collaboration Agreement”), in order to modify: (i) the scope of the licensed territory, (ii) milestone payments, (iii) royalty rates, and (iv) drug development obligations. In connection with the Amended Mundipharma Collaboration Agreement, we received a one-time $7 million payment from Mundipharma for our future research and development activities related to FOLOTYN. As a result of the Amended Mundipharma Collaboration Agreement, (a) Europe and Turkey were excluded from Mundipharma’s commercialization territory, (b) we are entitled to regulatory and sales-dependent milestone receipts of up to $16 million and $107 million , respectively (see Note 16(b)(vii) for July 2017 achievement), (c) we will receive tiered double-digit royalties based on net sales of FOLOTYN within Mundipharma’s licensed territories, and (d) we and Mundipharma will each bear our own FOLOTYN development costs. Effective as of May 1, 2015, we modified the Amended Mundipharma Collaboration Agreement to revise the conditions for our exercise of the option to gain commercialization rights in Switzerland from Mundipharma, as well as royalties payable to us (in the tiered double-digits) on Mundipharma's net sales in Switzerland. FOLOTYN Development Liability The fair value of the FOLOTYN Development Liability within our accompanying Condensed Consolidated Balance Sheets was estimated using the discounted income approach model. The unobservable inputs (i.e., "Level 3" inputs - see Note 2(xiii) ) in this valuation model that have the most significant effect on these liabilities include: (i) estimates of research and development personnel costs needed to perform the research and development services contractually required, (ii) estimates of expected cash outflows to third parties for these clinical services and supplies during the expected period of performance through 2031, and (iii) an appropriate discount rate for these expenditures. These inputs are reviewed by management on a quarterly basis for continued applicability. We adjust this liability during each quarterly period, with corresponding adjustments for incurred costs recorded as credits to “research and development” expense in our accompanying Condensed Consolidated Statements of Operations. FOLOTYN FOLOTYN FOLOTYN Balance at December 31, 2016 $ 861 $ 12,269 $ 13,130 Transfer from long-term to current in 2017 (4 ) 4 — (Less): Expenses incurred in 2017 (704 ) — (704 ) Balance at September 30, 2017 $ 153 $ 12,273 $ 12,426

Financial Commitments & Conting

Financial Commitments & Contingencies and License Agreements	9 Months Ended
	Sep. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Financial Commitments & Contingencies and License Agreement	COMMITMENTS & CONTINGENCIES AND LICENSE AGREEMENTS (a) Facility Leases We lease our principal executive office in Henderson, Nevada under a non-cancelable operating lease expiring April 30, 2019 . We also lease our research and development facility in Irvine, California under a non-cancelable operating lease expiring May 31, 2019 , in addition to several other administrative office leases. Each lease agreement contains scheduled rent increases which are accounted for on a straight-line basis. (b) In/Out Licensing Agreements and Co-Development Arrangements The in-license agreements for our commercialized and development-stage drug products provide us with territory-specific rights to their manufacture and distribution (including further sub-licensing/out-licensing, rights). We are generally responsible for all related clinical development costs, patent filings and maintenance costs, marketing costs, and liability insurance costs. We are also obligated to make specified milestone payments to our licensors upon the achievement of certain regulatory and sales milestones, and to pay royalties based on our net sales of all in-licensed products. We also enter into out-license agreements for territory-specific rights to our drug products which include one or more of: upfront license fees, royalties from our licensees’ sales, and/or milestone payments from our licensees’ sales or regulatory achievements. For certain development-stage drug products, we may enter into cost-sharing arrangements with our licensees and licensors. Our most significant of these agreements, and the key financial terms and our accounting for each, are summarized below: (i) ZEVALIN U.S.: In-Licensing and Development in the U.S. In December 2008, we acquired rights to commercialize and develop ZEVALIN in the U.S. as the result of a transaction with Cell Therapeutics, Inc. (“CTI”) through our wholly-owned subsidiary, RIT Oncology LLC (“RIT”). In accordance with the terms of assumed contracts, we are required to meet specified payment obligations, including a milestone payment to Corixa Corporation of $5 million based on our ZEVALIN sales in the U.S. (the “Corixa Liability”). This milestone has not yet been met, and $0.1 million for this potential milestone achievement is included within “acquisition-related contingent obligations” in our accompanying Condensed Consolidated Balance Sheets as of September 30, 2017 and December 31, 2016 , respectively. Our U.S. net sales-based ZEVALIN royalties are in the low to mid-single digits to Genentech, Inc. and in the mid-teens to Biogen Inc. (ii) ZEVALIN Ex-U.S.: In-License and Asset Purchase Agreement with Bayer Pharma In April 2012, through our wholly-owned subsidiary, Spectrum Pharmaceuticals Cayman, L.P., we completed a €19 million acquisition of licensing rights to market ZEVALIN outside of the U.S. from Bayer. ZEVALIN is currently approved in approximately 40 countries outside the U.S. for the treatment of B-cell NHL, including countries in Europe, Latin America, and Asia. We amended the agreement in February 2016, which adjusted our tiered royalty to Bayer from the single-digits to 20% . The term of the agreement, as amended, continues until the expiration of the last-to-expire ZEVALIN patent in the relevant country, or 15 years from the date of first commercial sale of ZEVALIN in such country, whichever is longer. (iii) ZEVALIN Ex-U.S.: Out-License Agreement with Dr. Reddy’s We executed an exclusive License Agreement with Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) in June 2014 for ZEVALIN distribution rights within India. The agreement term is 15 years from the receipt of pending approval of ZEVALIN from the Drug Controller General of India. In December 2014, upon our execution of a drug supply agreement, an upfront and non-refundable payment of $0.5 million was triggered and was paid to us in February 2015. The recognition of the applicable portion of this upfront receipt is reported on a straight-line basis, within “license fees and service revenue” on the Condensed Consolidated Statements of Operations over a 10 -year term through December 2024. Additionally, sales and regulatory milestone payments, each aggregating $1.5 million (for a total of $3 million ), are due to us when such milestones are achieved by Dr. Reddy’s, as well as an ongoing 20% royalty on their net sales of ZEVALIN in India. (iv) ZEVALIN Ex-U.S.: Out-License Agreement with Mundipharma In November 2015, we entered into an out-license agreement with Mundipharma for their commercialization of ZEVALIN in Asia (excluding India and Greater China), Australia, New Zealand, Africa, the Middle East, and Latin America (including the Caribbean islands). In return, we received $18 million (comprised of $15 million received in December 2015 and $3 million received in January 2016). Of these proceeds, $15 million was recognized within "license fees and service revenue" in the fourth quarter of 2015. Of the $3 million received in January 2016, $0.5 million was recognized for the three months ended September 30, 2016 , and $1.2 million and $1.3 million was recognized in the same caption for the nine months ended September 30, 2017 and 2016 , respectively (this $3 million was recognized in full by June 30, 2017). Mundipharma is required to reimburse us for our payment of royalties due to Bayer from their net sales of ZEVALIN (see Note 16(b)(ii)). We are also eligible to receive an additional $2 million upon Mundipharma's achievement of a specified sales milestone that, if/when achieved, will also be reported within "license fees and service revenue". (v) FUSILEV: In-License Agreement with Merck & Cie AG In May 2006, we amended and restated a license agreement with Merck & Cie AG (“Merck”), which we assumed in connection with our March 2006 acquisition of the assets of Targent, Inc. This provided us with an exclusive license to use regulatory filings related to FUSILEV, and a non-exclusive license under certain patents and know-how, to develop, manufacture, and sell FUSILEV in the field of oncology in North America. The contractual royalty percentage on our FUSILEV net sales due to Merck is set at the mid-single digits; however, in September 2017, we paid Merck $2.6 million in full settlement of all royalty obligations under the agreement. We are no longer contractually obligated to pay Merck any royalties on our future net sales of FUSILEV, though we remain obligated to a $0.2 million payment upon FDA approval of our oral form of FUSILEV. This regulatory milestone has not yet been met, and no amounts have been accrued in our accompanying Condensed Consolidated Balance Sheets for its potential achievement. (vi) FOLOTYN: In-License Agreement with Sloan-Kettering Institute, SRI International and Southern Research Institute In December 2002, Allos entered into an in-license agreement for the drug now marketed as FOLOTYN with Sloan-Kettering Institute for Cancer Research, SRI International, and Southern Research Institute. We assumed this agreement when we acquired Allos in September 2012. The agreement provides for our exclusive worldwide rights to a portfolio of patents and patent applications related to FOLOTYN, though we are required to fund certain development programs of the drug. In addition, we pay graduated royalties to our licensors based on our worldwide annual net sales of FOLOTYN (including that of our sub-licensees). These royalties are 8% of annual worldwide net sales up to $150 million ; 9% of annual worldwide net sales of $150 million through $300 million ; and 11% of annual worldwide net sales in excess of $300 million . In addition, milestones are due following receipt of regulatory approval milestone payments in certain territories. (vii) FOLOTYN: Out-License Agreement with Mundipharma As a result of our acquisition of Allos (see Note 9(c) ), we assumed “the Mundipharma Collaboration Agreement” as well as certain FOLOTYN clinical development obligations. Under the Mundipharma Collaboration Agreement, as amended (see Note 15 ), we retained full commercialization rights for FOLOTYN in the U.S. and Canada, with Mundipharma having exclusive rights to commercialize FOLOTYN in all other countries in the world, except in Europe and Turkey. We are contractually entitled to receive regulatory and sales milestone payments from Mundipharma upon its achievement of such milestones, which aggregate $16 million and $107 million , respectively, as well as tiered double-digit royalties on Mundipharma's net sales. In July 2017, FOLOTYN was approved in Japan for the treatment of adult patients with relapsed or refractory PTCL. Consequently, we received a $3 million from Mundipharma in August 2017 for this milestone achievement. This amount was recognized within "license fees and service revenue" on our Condensed Consolidated Statements of Operations for the three and nine months ending September 30, 2017 . In August 2017, FOLOTYN was commercially launched in Japan. This triggered a contractual milestone of $2.0 million from Mundipharma. This amount was recorded within "other receivables" on our Condensed Consolidated Balance Sheets and within "license fees and service revenue" on our Condensed Consolidated Statements of Operations for the three and nine months ending September 30, 2017 . (viii) EVOMELA: In-License Agreement with CyDex Pharmaceuticals, Inc. In March 2013, we completed the acquisition of exclusive global development and commercialization rights to EVOMELA from CyDex, a wholly-owned subsidiary of Ligand (see Note 9(b) ), and assumed responsibility for its then-ongoing clinical and regulatory development program. We filed a New Drug Application ("NDA") with the FDA in December 2015 for EVOMELA's use as a conditioning treatment prior to autologous stem cell transplant for patients with MM, and in March 2016, the FDA communicated its approval. Consequently, we made a $6 million contractual milestone payment to Ligand in April 2016. This amount was capitalized as "EVOMELA distribution rights" and is presented within "intangible assets, net of accumulated amortization and impairment charges" (see Note 3(f) ) within our accompanying Condensed Consolidated Balance Sheets as of September 30, 2017 . We are required to pay Ligand additional amounts of up to $60 million (exclusive of the $6 million paid in April 2016), upon our achievement of specified net sales thresholds. We are also responsible to pay Ligand royalties of 20% on our net sales of EVOMELA in all territories. (ix) MARQIBO: Acquisition of Talon Therapeutics, Inc. and Related Contingent Consideration Agreement In July 2013, we completed the acquisition of Talon, through which we obtained exclusive global development and commercialization rights to MARQIBO (see Note 9(a) ). As part of this acquisition, the former Talon stockholders have contingent financial rights that we have valued and presented on our accompanying Condensed Consolidated Balance Sheets as a $4.5 million and $1.3 million liability within “acquisition-related contingent obligations” as of September 30, 2017 and December 31, 2016 , respectively. The maximum payout value of these contingent financial rights to the former Talon stockholders is $195 million , assuming all sales and regulatory approval milestones are achieved by us. In addition, we are contractually obligated to pay royalties in the single digits on our net sales of MARQIBO and a portion of sublicensing revenue may be due upon our receipt of such revenue for MARQIBO. (x) QAPZOLA: License Agreements with Allergan, Inc. and NDDO Research Foundation In October 2008, we entered into an exclusive development and commercialization collaboration agreement with Allergan, Inc. ("Allergan") for QAPZOLA. Allergan paid us an up-front non-refundable fee of $41.5 million at execution (which we have recognized in full within “license fees and service revenue” by December 31, 2013). Concurrently we also entered into a letter agreement with NDDO Research Foundation (“NDDO”), pursuant to which we agreed to pay NDDO the following in relation to QAPZOLA milestones: (a) upon FDA acceptance of our NDA, the issuance of 25,000 of our common shares (which occurred in March 2016 and the $0.1 million value of these shares was included in "research and development" expense for the year ended December 31, 2016), and (b) upon FDA approval, a one-time payment of $0.3 million (which has not yet been met, and no amounts have been accrued in our accompanying Condensed Consolidated Balance Sheets for its potential achievement). In January 2013, we entered into a second amendment to the License, Development, Supply and Distribution Agreement with Allergan. This amendment relieved Allergan of its development and commercialization obligations and resulted in our acquisition of its rights in the U.S., Europe, and other territories, in exchange for our agreement to pay a tiered single-digit royalty on our sales of certain products containing QAPZOLA. (xi) QAPZOLA: Collaboration Agreement with Nippon Kayaku Co. LTD. In November 2009, we entered into a collaboration agreement with Nippon Kayaku Co., LTD. (“Nippon Kayaku”) for the development and commercialization of QAPZOLA in Asia, except North and South Korea (the “Nippon Kayaku Territory”). In addition, Nippon Kayaku received exclusive rights to QAPZOLA for the treatment of NMIBC in Asia (other than North and South Korea), including Japan and China. Nippon Kayaku will conduct QAPZOLA clinical trials in the Nippon Kayaku Territory pursuant to a development plan. Further, Nippon Kayaku will be responsible for all expenses relating to the development and commercialization of QAPZOLA in the Nippon Kayaku Territory. Under the terms of this agreement, Nippon Kayaku paid us an upfront fee of $15 million (which we recognized within “license fees and service revenue” in full by December 31, 2013). Under the terms of the agreement, we are entitled to receive $10 million and $126 million from Nippon Kayaku upon the achievement of certain regulatory and commercialization milestones, respectively (some of which are our responsibility to achieve). Nippon Kayaku is also obligated to pay us royalties on its net sales of QAPZOLA in the mid-teen digits. (xii) BELEODAQ: In-License and Collaboration Agreement with Onxeo In February 2010, we entered into an in-license and collaboration agreement with TopoTarget A/S (now Onxeo DK) (“Onxeo”) for the development and commercialization of BELEODAQ, as amended in October 2013. We paid Onxeo an upfront fee of $30 million (and agreed to additional payments described below) for rights in North America and India, with an option for China. We are contractually obligated to pay royalties in the mid-teen digits on our net sales of BELEODAQ. All development and studies of BELEODAQ are conducted under a joint development plan (of which we fund 70% and Onxeo funds 30% ). We have the final decision-making authority for all developmental activities in North America and India (and China upon our exercise of the option). Onxeo has final decision-making authority for all developmental activities in all other jurisdictions. In February 2014, upon FDA acceptance of our NDA, we were contractually obligated to issue Onxeo one million shares of our common stock and to make a $10 million payment. The aggregate value of this milestone at achievement was $17.8 million , and was recognized within “research and development” expense in the first quarter of 2014. In July 2014, we received approval from the FDA for BELEODAQ’s use for injection and treatment of relapsed or refractory peripheral T-cell lymphoma ("PTCL"). As a result, we made a second milestone payment to Onxeo of $25 million in November 2014. This amount was capitalized as "BELEODAQ distribution rights" and is presented within "intangible assets, net of accumulated amortization and impairment charges" (see Note 3(f) ). We are also contractually obligated to pay Onxeo upon our achievements of other regulatory events and sales thresholds, up to $88 million and $190 million , respectively. These milestone amounts are not included within “total liabilities” in our accompanying Condensed Consolidated Balance Sheets. (xiii) ROLONTIS: Co-Development and Commercialization Agreement with Hanmi Pharmaceutical Co. Ltd In October 2014, we exercised our option under a License Option and Research Collaboration Agreement dated January 2012 (as amended) with Hanmi Pharmaceutical Co. Ltd. ("Hanmi") for ROLONTIS (formerly known as “LAPS-G-CSF" or "SPI-2012”), a drug based on Hanmi’s proprietary LAPSCOVERY™ technology for the treatment of chemotherapy induced neutropenia. Under the terms of this agreement, as amended, we have primary financial responsibility for the ROLONTIS development plan and hold its worldwide rights (except for Korea, China, and Japan). We are contractually obligated to pay Hanmi royalties in the mid-teen digits on our net sales of ROLONTIS. In January 2016, the first patient was dosed with ROLONTIS in a clinical trial. This triggered our contractual milestone payment to Hanmi, and in April 2016, we (i) issued Hanmi 318,750 shares of our common stock, then valued at $2.3 million , and (ii) remitted a $0.4 million payment to the Internal Revenue Service on Hanmi's behalf for related tax obligations. This aggregate $2.7 million value was recognized within "research and development" expense in our accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2016 . We are responsible for further contractual payments upon our achievement of regulatory and sales milestones, up to $13 million and $225 million , respectively. These amounts are not included within "total liabilities" in our accompanying Condensed Consolidated Balance Sheets. (xiv) POZIOTINIB: In-License Agreement with Hanmi In February 2015, we executed an in-license agreement with Hanmi for POZIOTINIB, a pan-HER inhibitor in Phase 2 clinical trials (which has also shown single agent activity in the treatment of various cancer types during Phase I studies, including breast, gastric, colorectal, and lung cancers), and made an upfront payment for these rights. This payment was recognized within "research and development" expense in the Consolidated Statements of Operations for the year ended December 31, 2015. We are also contractually obliged to pay Hanmi royalties in the low to mid-teen digits on our net sales of POZIOTINIB. Under the terms of this agreement, we received the exclusive rights to commercialize POZIOTINIB, excluding Korea and China. Hanmi and its development partners are fully responsible for the completion of on-going Phase 2 trials in Korea. We are financially responsible for all other clinical studies. We are contractually obligated to make payments to Hanmi upon our achievement of certain regulatory and sales milestones, aggregating $33 million and $325 million , respectively. These amounts are not included within “total liabilities” in our accompanying Condensed Consolidated Balance Sheets. (xv) ZEVALIN, FOLOTYN, BELEODAQ, and MARQIBO: Out-License Agreement with Servier in Canada In January 2016, we out-licensed ZEVALIN, FOLOTYN, BELEODAQ, and MARQIBO to Servier (see Note 12 ). We received an aggregate $6 million of upfront proceeds in the first quarter of 2016, which was recognized within "license fees and service revenue" in our accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2016 . We are also entitled to milestone receipts (aggregating $2.0 million ) upon Servier's achievement of specific regulatory approvals, and a high single-digit royalty on its sales of these products. (c) Service Agreements In connection with the research and development of our drug products, we have entered into contracts with numerous third party service providers, such as radio-pharmacies, distributors, clinical trial centers, clinical research organizations, data monitoring centers, and with drug formulation, development and testing laboratories. The financial terms of these agreements are varied and generally obligate us to pay in stages, depending on achievement of certain events specified in the agreements, such as contract execution, reservation of service or production capacity, actual performance of service, or the successful accrual and dosing of patients. At each period end, we accrue for all services received, with such accruals based on factors such as estimates of work performed, patient enrollment, completion of patient studies and other events. Should we decide to discontinue and/or slow-down the work on any project, the associated costs for those projects would be limited to the extent of the work completed. Generally, we are able to terminate these contracts due to the discontinuance of the related project(s) and thus avoid paying for the services that have not yet been rendered. (d) Supply Agreements We have entered into certain supply agreements, or have issued purchase orders, which require us to make minimum purchases from vendors for the manufacture of our products. These commitments do not exceed our planned commercial requirements, and the contracted prices do not exceed their fair market value. (e) Employment Agreement We have entered into an employment agreement with our Chief Executive Officer under which cash compensation and benefits would become payable in the event of termination by us for any reason other than cause, his resignation for good reason, or upon a change in control of our Company. (f) Deferred Compensation Plan The Spectrum Pharmaceuticals, Inc. Deferred Compensation Plan (the “DC Plan”) is administered by the Compensation Committee of our Board of Directors and is intended to comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended. The DC Plan is maintained to provide deferred compensation benefits for a select group of our employees (the “DC Participants”). Under the DC Plan, we provide the DC Participants with the opportunity to make annual elections to defer up to a specified amount or percentage of their eligible cash compensation, and we have the option to make discretionary contributions. At September 30, 2017 and December 31, 2016 , the aggregate DC Plan deferrals by employees and our discretionary contributions totaled $10.3 million and $8.4 million , respectively, and are included within “other long-term liabilities” in the accompanying Condensed Consolidated Balance Sheets. (g) Litigation We are involved from time-to-time with various legal matters arising in the ordinary course of business. These claims and legal proceedings are of a nature we believe are normal and incidental to a pharmaceutical business, and may include product liability, intellectual property, employment matters, and other general claims. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are assessed at least quarterly and adjusted to reflect the impact of any settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. Although the ultimate resolution of these various matters cannot be determined at this time, we do not believe that such matters, individually or in the aggregate, will have a material adverse effect on our consolidated results of operations, cash flows, or financial condition. ANDA Litigation In 2016, the Company concluded regulatory and Abbreviated New Drug Application ("ANDA") litigation with respect to its products FUSILEV and FOLOTYN. All costs pertaining to these matters (incurred and accrued) have been recognized within "selling, general and administrative" expenses on the accompanying Condensed Consolidated Statements of Operations for all periods presented. Stockholder Litigation In re Spectrum Pharmaceuticals, Inc. Securities Litigation (Consol. Case Nos. 2:16-cv-07074 & 2:16-cv-02279). The Company and certain of its officers are named as defendants in this putative federal securities class action pending in the U.S. District Court for the District of Nevada. The operative complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 arising from statements regarding our business and the submission of an NDA for QAPZOLA to the U.S. Food & Drug Administration. The plaintiffs seek damages, interest, costs, attorneys’ fees, and other unspecified equitable relief. We believe that these claims are without merit, and intend to vigorously defend against these claims. Furthermore, the value of a potential settlement cannot be reasonably estimated given its highly uncertain nature as of September 30, 2017 .

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES We apply an estimated annual effective tax rate (“ETR”) approach for calculating a tax provision for interim periods, as required under GAAP. We recorded a benefit for income taxes of $1.4 million and $0.6 million for the nine months ended September 30, 2017 and 2016 , respectively. Our ETR differs from the U.S. federal statutory tax rate of 35% primarily as a result of nondeductible expenses, state income taxes, foreign income taxes, and the impact of a valuation allowance on our deferred tax assets. Our provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. A valuation allowance is established when it is more likely than not the future realization of all or some of the deferred tax assets will not be achieved. The evaluation of the need for a valuation allowance is performed on a jurisdiction by jurisdiction basis, and includes a review of all available positive and negative evidence. We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Any interest and penalties related to uncertain tax positions will be reflected in income tax expense. The intra period tax allocation rules require that we allocate the provision for income taxes between continuing operations and other categories of earnings, such as other comprehensive income. In periods where we have a year-to-date pretax loss from continuing operations and year-to-date pre-tax income in other categories of earnings, such as other comprehensive income, ASC 740-20-45-7 requires that we allocate the income tax provision to other categories of earnings, and then record a related tax benefit in continuing operations. For the three and nine months ended September 30, 2017 , we recognized a net loss from investments and currency transactions within "other comprehensive income" while sustaining losses from continuing operations. As a result of the required allocation under ASC 740-20-45-7 , we recorded income tax expense of $2.0 million and $2.0 million in "other comprehensive income" on the accompanying Condensed Consolidated Statements of Comprehensive Loss, and a benefit for income taxes of $1.5 million and $1.4 million within "benefit for income taxes" on the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2017 . For the three and nine months ended September 30, 2016, we recognized a net income from investments and currency transactions within other comprehensive income while sustaining losses from continuing operations. As a result of the required allocation under ASC 740-20-45-7 , we recorded tax expense of $0.3 million and $0.9 million in "other comprehensive income" on the accompanying Condensed Consolidated Statements of Comprehensive Loss, and a tax benefit of $0.5 million and $0.6 million within "benefit for income taxes" on the Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016. On January 1, 2017, we adopted ASU 2016-09 , Improvements to Employee Share-Based Payment Accounting, on a modified prospective basis . Under ASU 2016-09 , differences between the tax deduction for share based awards and the related compensation expenses recognized under ASC 718 are now accounted for as a component of the provision for income taxes. In addition, ASU 2016-09 eliminated the requirement that excess tax benefits from share based compensation reduce taxes payable prior to being recognized in the financial statements. As of December 31, 2016, we had cumulative excess benefits related to share based compensation of $2.7 million which had not been reflected as a deferred tax asset. As a result of the adoption of ASU 2016-09 , the excess benefits were reclassified to our net operating loss carryover resulting in an increase in our deferred tax assets and valuation allowance of $2.7 million as of January 1, 2017. There was no impact to retained earnings as a result of the adoption of ASU 2016-09 on January 1, 2017. In addition, there was no impact on the three and nine months ended September 30, 2017 from the adoption of ASU 2016-09 due to the Company having a full valuation allowance.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Stockholders' Equity	STOCKHOLDERS' EQUITY Sale of Common Stock - December 2015 and August 2017 ATM Agreements In December 2015, we entered into a collective at-market-issuance sales agreement with FBR Capital Markets & Co., MLV & Co. LLC, and H.C. Wainwright & Co., LLC. (the “December 2015 ATM Agreement”). The December 2015 ATM Agreement allowed us to raise gross proceeds of up to $100 million from the sale of our common stock through these brokers under our shelf registration statement on Form S-3 (declared effective by the SEC on February 3, 2016; File No. 333-208760) (the "Registration Statement"). As of July 31, 2017, we fully utilized this ATM Facility. In August 2017, we entered into a collective at-market-issuance sales agreement with FBR Capital Markets & Co., MLV & Co. LLC, and H.C. Wainwright & Co., LLC. (the "August 2017 ATM Agreement"). The August 2017 ATM Agreement allows us to raise gross proceeds of up to $150 million from the sale of our common stock through these brokers under the Registration Statement. We sold and issued shares of our common stock under both the December 2015 and August 2017 ATM Agreements, as summarized in the following table: Description of Financing Transaction No. of Common Shares Issued Proceeds Received (Net of Broker Commissions and Fees ) Common shares issued pursuant to the December 2015 ATM Agreement between April 1, 2016 and September 30, 2016 (no shares issued in remainder of 2016) 10,890,915 $ 73,869 Common shares issued pursuant to the December 2015 ATM Agreement between July 1, 2017 and July 31, 2017 3,243,882 $ 23,745 Common shares issued pursuant to the August 2017 ATM Agreement between August 1, 2017 and September 30, 2017 9,314,250 $ 90,221 Conversion of Series E Convertible Voting Preferred Stock In June 2016, our then outstanding 20 shares of Series E convertible voting preferred stock were converted (at the election of the preferred stockholders) into an aggregate of 40,000 common shares; a $6 thousand dividend in arrears was paid upon this conversion.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2017
Subsequent Events [Abstract]
Subsequent Event	SUBSEQUENT EVENTS Open Market Purchases of 2018 Convertible Notes and Conversion Hedge Unwind in October 2017 On October 12, 2017, we completed an open market purchase of our 2018 Convertible Notes, aggregating 69,472 note units (equivalent to $69.5 million principal value) for $27.3 million in cash and 5.4 million newly-issued shares of our common stock. We will determine and recognize the gain (loss) on the retirement of these 2018 Convertible Notes within "other income (expense), net" on the Consolidated Statements of Operations for the year ended December 31, 2017. After this purchase, $40.6 million in principal of our 2018 Convertible Notes remains outstanding; this amount, as well as cash and common share entries, will be reflected in our Consolidated Balance Sheets as of December 31, 2017. Concurrent with this open market purchase, we also unwound a portion of our previously sold warrants and previously purchased call options that were part of our "conversion hedge" (see Note 14 ) for aggregate net proceeds of $5.8 million . We will record these net cash proceeds and corresponding net increase to "additional paid-in capital" in the Consolidated Balance Sheets as of December 31, 2017. Sale of Common Stock Under ATM Agreement in October 2017 In October 2017, we sold and issued 1.0 million shares of our common stock for net proceeds of $14.3 million under the August 2017 ATM Agreement (see Note 18 ). These shares and proceeds are not included in our "common stock" and "cash and cash equivalents" on our Condensed Consolidated Balance Sheets at September 30, 2017, though they will be reflected as of December 31, 2017.

Description of Business, Basi27

Description of Business, Basis of Presentation, and Operating Segment (Policies)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Abstract]
Description of Business	Description of Business Spectrum Pharmaceuticals, Inc. (“Spectrum”, the “Company”, “we”, “our”, or “us”) is a biotechnology company, with a primary strategy comprised of acquiring, developing, and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. We have an in-house clinical development organization with regulatory and data management capabilities, and a commercial infrastructure and field sales force for our marketed products. Currently, we have six approved oncology/hematology products (FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, and EVOMELA) that target different types of cancer including: non-Hodgkin's lymphoma ("NHL"), advanced metastatic colorectal cancer, acute lymphoblastic leukemia, and multiple myeloma ("MM"). We also have three drugs in mid-to-late stage development (in Phase 2 or Phase 3 clinical trials): • ROLONTIS (formerly referred to as SPI-2012 or LAPS-G-CSF) for chemotherapy-induced neutropenia. • QAPZOLA (formerly referred to as APAZIQUONE) for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer ("NMIBC"). • POZIOTINIB, a novel pan-HER inhibitor used in the treatment of patients with a variety of solid tumors, including breast and lung cancer.
Basis of Presentation	Basis of Presentation Interim Financial Statements The interim financial data for the three and nine months ended September 30, 2017 and 2016 , respectively, is unaudited, and is not necessarily indicative of our operating results for a full year. In the opinion of our management, the interim data includes normal and recurring adjustments necessary for a fair presentation of our financial results for the three and nine months ended September 30, 2017 and 2016 . Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) have been condensed or omitted pursuant to U.S. Securities and Exchange Commission (“SEC”) rules and regulations relating to interim financial statements. The December 31, 2016 balances reported herein are derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2016 , filed with the SEC on March 14, 2017 (our "2016 Form 10-K"). The accompanying Condensed Consolidated Financial Statements should be read in conjunction with our audited Consolidated Financial Statements and Notes thereto included in our 2016 Form 10-K. Principles of Consolidation The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with GAAP and with the rules and regulations of the SEC. These financial statements include the financial position, results of operations, and cash flows of Spectrum and its subsidiaries, all of which are wholly-owned (except for Spectrum Pharma Canada ("SPC"), as discussed below). All inter-company accounts and transactions among these legal entities have been eliminated in consolidation. Variable Interest Entity We own fifty -percent of SPC, a legal entity organized in Quebec, Canada in January 2008. Some of our clinical studies are conducted through this “variable interest entity” (as defined under applicable GAAP). We fund all of SPC’s operating costs, and since we assume all risks and rewards for this entity, we meet the GAAP criteria as being its “primary beneficiary.” Accordingly, SPC’s balance sheets and statements of operations are included in our Condensed Consolidated Financial Statements as if it were a wholly-owned subsidiary for all periods presented.
Operating Segment	Operating Segment We operate in one reportable operating segment that is focused exclusively on developing and commercializing oncology and hematology drug products. For the three and nine months ended September 30, 2017 and 2016 , respectively, all of our revenue and related expenses were solely attributable to these activities. Substantially all of our assets (excluding our cash and securities held in certain foreign bank accounts and by our Ex-U.S. entities, and our ZEVALIN distribution rights for the Ex-U.S. territory) are held in the U.S.
Revenue Recognition	Revenue Recognition (a) Product Sales : We sell our products to wholesalers/distributors (i.e., our customers), except for our U.S. sales of ZEVALIN in which case the end-user (i.e., clinic or hospital) is our customer. Our wholesalers /distributors in turn sell our products directly to clinics, hospitals, and private oncology-based practices. Revenue from product sales is recognized when title and risk of loss have transferred to our customer, and the following additional criteria are met: (1) appropriate evidence of a binding arrangement exists with our customer; (2) price is substantially fixed or determinable; (3) collection from our customer is reasonably assured; (4) our customer’s obligation to pay us is not contingent on resale of the product; (5) we do not have significant continued performance obligations to our customer; and (6) we have a reasonable basis to estimate returns. Our gross revenue is reduced by our gross-to-net (“GTN”) estimates each period, resulting in our reported “product sales, net” in the accompanying Condensed Consolidated Statements of Operations. We defer revenue recognition in full if these estimates are not reasonably determinable at the time of sale. These estimates are based upon information received from external sources (such as written or oral information obtained from our customers with respect to their period-end inventory levels and their sales to end-users during the period), in combination with management’s informed judgments. Due to the inherent uncertainty of estimates, the actual amount we incur may be materially different than our GTN estimates, and require prospective revenue adjustments in periods after the initial sale was recorded. Our GTN estimates are comprised of the following categories: Product Returns Allowances : Our FUSILEV, MARQIBO, and BELEODAQ customers are permitted to return purchased product beginning at its expiration date and within six months thereafter. Our EVOMELA customers are permitted to return purchased product beginning at six months prior to its expiration date, and within 12 months thereafter (as well as for overstock inventory, as determined by end-users). Returned product is generally destroyed and not resold. Returns outside of the above-referenced criteria or for expiry of ZEVALIN and FOLOTYN are not contractually, or customarily, allowed. We estimate expected product returns for our allowance based on our historical return rates. Government Chargebacks : Our products are subject to pricing limits under certain federal government programs (e.g., Medicare and 340B Drug Pricing Program). Qualifying entities (i.e., end-users) purchase products from our customers at their qualifying discounted price. The chargeback amount we incur represents the difference between our contractual sales price to our customer, and the end-user’s applicable discounted purchase price under the government program. There may be significant lag time between our reported net product sales and our receipt of the corresponding government chargeback claims from our customers. Prompt Pay Discounts : Discounts for prompt payment are estimated at the time of sale, based on our eligible customers’ prompt payment history and the contractual discount percentage. Commercial Rebates : Commercial rebates are based on (i) our estimates of end-user purchases through a group purchasing organization ("GPO"), (ii) the corresponding contractual rebate percentage tier we expect each GPO to achieve, and (iii) our estimates of the impact of any prospective rebate program changes made by us. Medicaid Rebates : Our products are subject to state government-managed Medicaid programs, whereby rebates are issued to participating state governments. These rebates arise when a patient treated with our product is covered under Medicaid, resulting in a discounted price for our product under the applicable Medicaid program. Our Medicaid rebate accrual calculations require us to project the magnitude of our sales, by state, that will be subject to these rebates. There is a significant time lag in us receiving rebate notices from each state (generally several months or longer after our sale is recognized). Our estimates are based on our historical claim levels by state, as supplemented by management’s judgment. Distribution, Data, and GPO Administrative Fees : Distribution, data, and GPO administrative fees are paid to authorized wholesalers/distributors of our products (except for U.S. sales of ZEVALIN) for various commercial services including: contract administration, inventory management, delivery of end-user sales data, and product returns processing. These fees are based on a contractually-determined percentage of our applicable sales. (b) License Fees : Our out-license arrangements with licensees for their limited rights to market our product(s) may include one or more of the following forms of consideration: (a) upfront license fees, (b) royalties from our licensees’ sales, (c) milestone receipts from our licensees’ sales, and (d) milestone receipts upon regulatory achievements by us or our licensees. We recognize revenue from these categories based on the contractual terms that establish the legal rights and obligations between us and our licensees. We complete the following steps in determining the dollar amount and timing of revenue recognition from our license fees: (i) We first assess the number of “units of accounting” for the elements in our out-license arrangements in accordance with multiple element arrangement guidance. We consider if elements (deliverables) have standalone value, and if standalone value does not exist for a deliverable, it is combined (as applicable) with other deliverables until the "bundle" has standalone value (as a single unit of accounting). (ii) Next, we allocate arrangement consideration among the separate units of accounting (using the "relative selling price method"). (iii) Finally, we evaluate the timing of revenue recognition, which is impacted by the nature of the consideration to which we are entitled, as follows: (a) Upfront license fees : We consider whether upfront license fees are earned (i.e., realized) at the time of contract execution (i.e., when the license rights transfer to the customer) or over the actual (or implied) contractual term of the out-license. We give specific consideration to whether we have any on-going contractual service obligations to the licensee, including any requirements for us to provide on-going support services, and/or for us to supply drug products for the licensee’s future sales. As a result, we may either recognize all upfront license fees as revenue in the period of contract execution, or recognize these fees over the actual (or implied) contractual term of the out-license. (b) Royalties : We recognize revenue in the period that our licensees report product sales to us in their territory for which we are contractually entitled to a percentage-based royalty receipt (i.e., representing the period when earned and realizable). (c) Sales milestones : We recognize revenue in the period that our licensees report achievement of annual or aggregate product sales levels in their territories for which we are contractually entitled to a specified lump-sum receipt (i.e., representing the period when earned and realizable). (d) Regulatory milestones : Under the terms of the respective out-license, regulatory achievements may either be our responsibility, or that of our licensee. • When our licensee is responsible for the achievement of the regulatory milestone (and we have no on-going obligations), we recognize this revenue in the period that our product achieves specified regulatory approvals for which we are contractually entitled to a fixed receipt (i.e., representing the period when earned and realizable). • When we are responsible for the achievement of the regulatory milestone, we recognize this revenue in the period that our product achieves specified regulatory approvals for which we are contractually entitled to a fixed receipt. Regulatory approvals by governmental agencies are inherently uncertain, and require our substantial cost and effort in completing our submission for potential approval. Therefore, these regulatory milestones are “substantive” and these fixed receipts remain at-risk (i.e. unearned and unrealizable) until the period of achievement. We believe the amounts we are entitled to receive upon our achievement relates solely to our past performance and is commensurate with either (i) our performance in achieving the milestone, or (ii) the resulting enhancement in value of the drug compound. (c) Service Revenue : We receive fees under certain arrangements for (a) sales and marketing services, (b) supply chain services, (c) research and development services, and (d) clinical trial management services. Payment for these services may be triggered by (i) an established fixed-fee schedule, (ii) the completion of product delivery in our capacity as a procurement agent, (iii) the successful completion of a phase of development, (iv) favorable results from a clinical trial, and/or (v) regulatory approval events. We consider whether revenue associated with these service arrangements is “realizable and earned” each reporting period, based on our completed services or deliverables during the reporting period, and the contractual terms of the arrangement (which typically includes fee schedules). For any/all milestone achievements in the reporting period that contractually result in fixed payments due to us, we apply the “milestone method” of revenue recognition. Accordingly, this revenue recognition occurs as each “substantive” milestone (as discussed below) is achieved by us, since (1) all contingencies associated with each milestone is resolved upon its achievement, (2) the milestone achievement relates solely to our past performance, and (3) no remaining milestone performance obligations exist in relation to our receipt of payment. In recognizing revenue under the milestone method, we first assess the number of “units of accounting” in the arrangement. We consider if the separate “deliverable” has standalone value to our licensee, and if standalone value does not exist for a deliverable, it is combined with other deliverables until the "bundle" has standalone value. The allocation of arrangement consideration and the recognition of revenue is determined for those combined deliverables as a single unit of accounting. This includes allocation of consideration associated with milestones achieved by our licensees. Next, we measure and allocate arrangement consideration among the separate units of accounting. This fixed or determinable consideration is allocated to the units of accounting using the "relative selling price method". Variable fees subsequently earned (other than substantive milestone payments) are allocated to the units of accounting on the same basis. We determine whether the milestone is substantive by considering (i) the extent of our effort to achieve the milestone and/or the enhancement of the value of the delivered item(s) as a result of milestone achievement, (ii) whether the milestone achievement relates solely to our past performance, and (iii) if the milestone payment is reasonable relative to all of the deliverables and payment terms (including other potential milestone consideration) within the arrangement. For service contracts without milestones, we recognize revenue when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) services have been rendered, (iii) fees are fixed or determinable, and (iv) collectability is reasonably assured. (d) New Revenue Recognition Standard : ASU No. 2014-09 , Revenue from Contracts with Customers (Topic 606) (“ ASU 2014-09 ”), is effective for us beginning January 1, 2018. This new accounting standard requires that we recognize revenue in a manner that reasonably reflects the delivery of our goods or services to customers in return for expected consideration. To achieve this core principle, ASU 2014-09 provides the following steps in evaluating revenue arrangements: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation. We are substantially complete with our evaluation of this new revenue standard, including (i) the impact on the value and timing of our revenue recognition for product sales, out-license arrangements, and service arrangements, (ii) the financial reporting transition requirements for adoption, and (iii) expanded footnote disclosures in our financial statements. We believe the adoption of ASU 2014-09 will not result in a material change of revenue recognition for our current product sales and out-license arrangements. We presently have no active service arrangements, though this new accounting standard would not have materially affected our historical revenue accounting practices for those types of arrangements. We will apply the "modified retrospective”transition method to implement ASU 2014-09 on January 1, 2018 (i.e., recognition of the cumulative effect of initially applying this standard to the opening balance of retained earnings), and as applicable, will include expanded revenue footnote disclosure requirements, beginning with our Form 10-Q for the period ended March 31, 2018.
Cash and Cash Equivalents	Cash and Cash Equivalents Our cash and cash equivalents consist of bank deposits and highly liquid investments with maturities of three months or less from the purchase date.
Marketable Securities	Marketable Securities Our marketable securities consist of our holdings in mutual funds and bank certificates of deposit ("Bank CDs"). Since we classify these securities as “available-for-sale” under applicable GAAP, any unrealized gains or losses from their change in value is reflected in “unrealized gain on available-for-sale securities” on the accompanying Condensed Consolidated Statements of Comprehensive Loss. Realized gains and losses on available-for-sale securities are included in “other income, net” on the accompanying Condensed Consolidated Statements of Operations.
Accounts Receivable, Net of Allowance for Doubtful Accounts	Accounts Receivable, Net of Allowance for Doubtful Accounts Our accounts receivables are derived from our product sales and license fees (receivables related to our service revenue is recorded in "other receivables"), and do not bear interest. The allowance for doubtful accounts is management’s best estimate of the amount of probable credit losses in our existing accounts receivable. Account balances are charged off against the allowance after appropriate collection efforts are exhausted.
Inventories	Inventories We value our inventory at the lower of (i) the actual cost of its purchase or manufacture, or (ii) its current market value. Inventory cost is determined on the first-in, first-out method. We regularly review our inventory quantities in process of manufacture and on hand. When appropriate, we record a provision for obsolete and excess inventory to derive its new cost basis, which takes into account our sales forecast by product and corresponding expiry dates of each product lot. Direct and indirect manufacturing costs related to the production of inventory prior to U.S. Food and Drug Administration ("FDA") approval are expensed through “research and development” on the accompanying Condensed Consolidated Statements of Operations, rather than being capitalized to inventory cost.
Property and Equipment, Net of Accumulated Depreciation	Property and Equipment, Net of Accumulated Depreciation Our property and equipment is stated at historical cost, and is depreciated on a straight-line basis over an estimated useful life that corresponds with its designated asset category. We evaluate the recoverability of “long-lived assets” (which includes property and equipment) whenever events or changes in circumstances in our business indicate that the asset’s carrying amount may not be recoverable through on-going operations.
Goodwill and Intangible Assets, Net of Accumulated Amortization and Impairment Charges	Goodwill and Intangible Assets, Net of Accumulated Amortization and Impairment Charges Our goodwill represents the excess of our business acquisition cost over the estimated fair value of the net assets acquired in the corresponding transaction. Goodwill has an indefinite accounting life and is therefore not amortized. Instead, goodwill is evaluated for impairment on an annual basis (as of each October 1 st ), unless we identify impairment indicators that would require earlier testing. We evaluate the recoverability of indefinite-lived intangible assets at least annually, or whenever events or changes in our business indicate that an intangible asset’s (whether indefinite or definite-lived) carrying amount may not be recoverable. Such circumstances could include, but are not limited to the following: (a) a significant decrease in the market value of an asset; (b) a significant adverse change in the extent or manner in which an asset is used; or (c) an accumulation of costs significantly in excess of the amount originally expected for the acquisition of an asset. Intangible assets with finite useful lives are amortized over their estimated useful lives on a straight-line basis. We review these assets for potential impairment if/when facts or circumstances suggest that the carrying value of these assets may not be recoverable.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation expense for equity awards granted to our employees and members of our board of directors is recognized on a straight-line basis over each award's vesting period. Recognized compensation expense is net of an estimated forfeiture rate, representing the percentage of awards that are expected to be forfeited (by termination of employment or service) prior to vesting. We use the Black-Scholes option pricing model to determine the fair value of stock options (as of the date of grant) which carry service conditions for vesting. We use the Monte Carlo valuation model to value equity awards (as of the date of grant) which carry combined market conditions and service conditions for vesting. The calculation of the fair value of stock options and the recognition of stock-based compensation expense requires uncertain assumptions, including (a) the pre-vesting forfeiture rates of the awards, (b) the expected term of our stock options, (c) our stock price volatility over its expected term (and that of our designated peer group with respect to certain market-based awards), and (d) the "risk-free" interest rate over the expected term. We estimate forfeiture rates based on our employees’ overall forfeiture history, which we believe will be representative of future results. We estimate the expected term of stock options granted based on our employees’ historical exercise patterns, which we believe will be representative of their future behavior. We estimate the volatility of our common stock on the date of grant based on historical volatility of our common stock for a look-back period that corresponds with the expected term. We estimate the risk-free interest rate based upon the U.S. Treasury yields in effect at award grant, for a period equaling the expected term of the stock option.
Foreign Currency Translation	Foreign Currency Translation We translate the assets and liabilities of our foreign subsidiaries that are stated in their functional currencies (i.e., local operating currencies), to U.S. dollars at the rates of exchange in effect at the reported balance sheet date. Revenues and expenses are translated using the monthly average exchange rates during the reported period. Unrealized gains and losses from the translation of our subsidiaries’ financial statements (that are initially denominated in the corresponding functional currency) are included as a separate component of “accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets. We record foreign currency transactions, when initially denominated in a currency other than the respective functional currency of our subsidiary, at the prevailing exchange rate on the date of the transaction. Resulting unrealized foreign exchange gains and losses from transactions with third parties are included in “accumulated other comprehensive income (loss)” in the Condensed Consolidated Balance Sheets. Beginning April 1, 2015, all unrealized foreign exchange gains and losses associated with our intercompany loans are included in "accumulated other comprehensive income (loss)" in the Condensed Consolidated Balance Sheets, as these loans with our foreign subsidiaries are not expected to be settled in the "foreseeable future."
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share We calculate basic and diluted net loss per share using the weighted average number of common shares outstanding during the periods presented. In periods of a net loss, basic and diluted loss per share is the same. For the diluted earnings per share calculation, we adjust the weighted average number of common shares outstanding to include only dilutive stock options, warrants, and other common stock equivalents outstanding during the period.
Income Taxes	Income Taxes Deferred tax assets and liabilities are recorded based on the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the financial statements, as well as operating losses and tax credit carry forwards using enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. Realization of deferred tax assets is dependent upon future earnings, the timing and amount of which are uncertain. We have recorded a valuation allowance to reduce our deferred tax assets, because we believe that, based upon a weighting of positive and negative factors, it is more likely than not that these deferred tax assets will not be realized. If/when we were to determine that our deferred tax assets are realizable, an adjustment to the corresponding valuation allowance would increase our net income in the period that such determination was made. In the event that we are assessed interest and/or penalties from taxing authorities that have not been previously accrued, such amounts would be included in “benefit for income taxes” within the Condensed Consolidated Statements of Operations in the period the notice was received.
Research and Development Costs	Research and Development Costs Our research and development costs are expensed as incurred, or as certain milestone payments become due, which are generally triggered by contractual clinical or regulatory events.
Fair Value Measurements	Fair Value Measurements We determine measurement-date fair value based on the proceeds that would be received through the sale of the asset, or that we would pay to settle or transfer the liability, in an orderly transaction between market participants. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include the following: Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that are publicly accessible at the measurement date. Level 2: Observable prices that are based on inputs not quoted on active markets, but that are corroborated by market data. These inputs may include quoted prices for similar assets or liabilities or quoted market prices in markets that are not active to the general public. Level 3: Unobservable inputs are used when little or no market data is available.

Balance Sheet Account Detail (T

Balance Sheet Account Detail (Tables)	9 Months Ended
	Sep. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash And Cash Equivalent Marketable Securities Unrealized Gain Table	The following is a summary of our presented “cash and cash equivalents” and “marketable securities”: Marketable Securities Cost Gross Gross Estimated Cash and Cash Current Long September 30, 2017 Bank deposits $ 21,574 $ — $ — $ 21,574 $ 21,574 $ — $ — Money market funds 225,894 — — 225,894 225,894 — — Bank certificates of deposits 248 — — 248 — 248 — Total cash and cash equivalents and marketable securities $ 247,716 $ — $ — $ 247,716 $ 247,468 $ 248 $ — December 31, 2016 Bank deposits $ 23,915 $ — $ — $ 23,915 $ 23,915 $ — $ — Money market funds 128,563 — — 128,563 128,563 — — Bank certificates of deposits 5,991 — — 5,991 5,744 247 — Total cash and cash equivalents and marketable securities $ 158,469 $ — $ — $ 158,469 $ 158,222 $ 247 $ —
Schedule of Property and Equipment Net of Accumulated Depreciation	“Property and equipment, net of accumulated depreciation” consist of the following: September 30, 2017 December 31, 2016 Computer hardware and software $ 2,933 $ 2,550 Laboratory equipment 622 622 Office furniture 218 211 Leasehold improvements 2,938 2,912 Property and equipment, at cost 6,711 6,295 (Less): Accumulated depreciation (6,096 ) (5,846 ) Property and equipment, net of accumulated depreciation $ 615 $ 449
Components of Inventories	“Inventories” consist of the following: September 30, 2017 December 31, 2016 Raw materials $ 1,683 $ 2,991 Work-in-process 7,457 7,838 Finished goods 3,439 2,305 (Less:) Non-current portion of inventories included within "other assets" * (3,596 ) (4,419 ) Inventories $ 8,983 $ 8,715 * The "non-current" portion of inventories is presented within "other assets" in the accompanying Condensed Consolidated Balance Sheets at September 30, 2017 and December 31, 2016 , respectively. This value of $3.6 million at September 30, 2017 represents product that we expect to sell beyond September 30, 2018
Prepaid Expenses and Other Assets	“Prepaid expenses and other assets” consist of the following: September 30, 2017 December 31, 2016 Prepaid insurance $ 185 $ 721 Inventory other 712 1,458 Other miscellaneous prepaid operating expenses 2,060 1,751 Prepaid expenses and other assets $ 2,957 $ 3,930
Schedule of Other Receivables	“Other receivables” consist of the following: September 30, 2017 December 31, 2016 FOLOTYN milestone for first sale in Japan (Note 16(b)(vii) ) 2,000 — CASI note - short term* 1,515 — Other miscellaneous receivables** 1,033 239 Employee receivables*** 857 — Reimbursements due from development partners for incurred research and development expenses 418 1,796 Insurance receivable 53 500 Receivable for contracted sales and marketing services ( Note 13 ) — 1,831 Income tax receivable — 1,388 Other receivables $ 5,876 $ 5,754 * This full balance was prospectively reclassified beginning March 31, 2017 to "other receivables" (presented within current assets on the accompanying Condensed Consolidated Balance Sheets) from "other assets" (presented within non-current assets) due to this note's maturity date - see Note 10 . ** As of September 30, 2017, this balance is inclusive of $0.6 million of Medicaid rebate credits to be applied against future invoices for each respective state program. *** This balance represents amounts due to us for exercises of stock options by employees. These exercises were executed by September 30, 2017, but the cash receipts did not post to our bank account until October 2017.
Components of Intangible Assets Net of Accumulated Amortization	“Intangible assets, net of accumulated amortization and impairment charges” consist of the following: September 30, 2017 Historical Accumulated Foreign Impairment Net Amount Full Remaining MARQIBO IPR&D (NHL and other novel indications) $ 17,600 $ — $ — $ — $ 17,600 n/a n/a EVOMELA distribution rights (1) 7,700 (888 ) — — 6,812 156 138 BELEODAQ distribution rights 25,000 (6,094 ) — — 18,906 160 121 MARQIBO distribution rights 26,900 (16,102 ) — — 10,798 81 30 FOLOTYN distribution rights (2) 118,400 (50,843 ) — — 67,557 152 62 ZEVALIN distribution rights – U.S. 41,900 (36,688 ) — — 5,212 123 18 ZEVALIN distribution rights – Ex-U.S. 23,490 (16,579 ) (2,763 ) — 4,148 96 30 FUSILEV distribution rights (3) 16,778 (9,618 ) — (7,160 ) — 56 0 FOLOTYN out-license (4) 27,900 (13,874 ) — (1,023 ) 13,003 110 58 Total intangible assets $ 305,668 $ (150,686 ) $ (2,763 ) $ (8,183 ) $ 144,036 (1) The FDA approval of EVOMELA in March 2016 triggered a $6 million payment due to CyDex Pharmaceuticals, Inc. (a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated ("Ligand")). This event also resulted in a reclassification of our $7.7 million "EVOMELA IPR&D" to "EVOMELA distribution rights" due to our ability to begin its commercialization with this FDA approval. Amortization commenced on April 1, 2016, in accordance with our capitalization policy for intangible assets. (2) Beginning June 2016, we adjusted the amortization period of our FOLOTYN distribution rights to November 2022 from March 2025, representing the period through which we expect to have patent protection from generic competition (see Note 16(g) ). (3) On February 20, 2015, the U.S. District Court for the District of Nevada found the patent covering FUSILEV to be invalid, which was upheld on appeal. On April 24, 2015, Sandoz Inc. began to commercialize a generic version of FUSILEV. This represented a “triggering event” under applicable GAAP in evaluating the value of our FUSILEV distribution rights as of March 31, 2015, resulting in a $7.2 million impairment charge (non-cash) in the first quarter of 2015. We accelerated amortization expense recognition in 2015 for the then remaining net book value of FUSILEV distribution rights. (4) On May 29, 2013, we amended our FOLOTYN collaboration agreement with Mundipharma International Corporation Limited ("Mundipharma"). As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and their royalty rates and milestone payments to us were modified. This constituted a change under which we originally valued the FOLOTYN out-license as part of business combination accounting, resulting in an impairment charge (non-cash) of $1.0 million in the second quarter of 2013. December 31, 2016 Historical Accumulated Foreign Impairment Net Amount MARQIBO IPR&D (NHL and other novel indications) $ 17,600 $ — $ — $ — $ 17,600 EVOMELA distribution rights 7,700 (444 ) — — 7,256 BELEODAQ distribution rights 25,000 (4,688 ) — — 20,312 MARQIBO distribution rights 26,900 (12,863 ) — — 14,037 FOLOTYN distribution rights 118,400 (41,036 ) — — 77,364 ZEVALIN distribution rights – U.S. 41,900 (34,083 ) — — 7,817 ZEVALIN distribution rights – Ex-U.S. 23,490 (13,649 ) (5,038 ) — 4,803 FUSILEV distribution rights 16,778 (9,618 ) — (7,160 ) — FOLOTYN out-license 27,900 (11,832 ) — (1,023 ) 15,045 Total intangible assets $ 305,668 $ (128,213 ) $ (5,038 ) $ (8,183 ) $ 164,234
Estimated Intangible Asset Amortization Expense	Estimated intangible asset amortization expense for the remainder of 2017 and the five succeeding fiscal years and thereafter is as follows: Years Ending December 31, Remainder of 2017 $ 6,930 2018 27,719 2019 25,114 2020 19,761 2021 18,266 2022 15,882 2023 and thereafter 12,764 $ 126,436
Schedule of Goodwill	“Goodwill” is comprised of the following: September 30, 2017 December 31, 2016 Acquisition of Talon (MARQIBO rights) $ 10,526 $ 10,526 Acquisition of ZEVALIN Ex-U.S. distribution rights 2,525 2,525 Acquisition of Allos (FOLOTYN rights) 5,346 5,346 Foreign currency exchange translation effects (266 ) (511 ) Goodwill $ 18,131 $ 17,886
Summary of Other Assets	“Other assets” are comprised of the following: September 30, 2017 December 31, 2016 Equity securities (see Note 10 )* $ 17,751 $ 11,533 Promissory note receivable - long term (see Note 10 )** — 1,510 Research & development supplies and other 267 224 Executive officer life insurance – cash surrender value 14,122 11,863 Inventories - non-current portion 3,596 4,419 Other assets $ 35,736 $ 29,549 * These equity securities in CASI were excluded from “marketable securities” (see Note 3(a) ) due to our intent to hold them for at least one year beyond September 30, 2017 . The unrealized gain on these "available-for-sale" equity securities are recognized as an increase to "other assets" and "accumulated deficit" (as a component of "other comprehensive income") within the accompanying Condensed Consolidated Balance Sheets and totaled $3.9 million , net of income tax, for the nine months ended September 30, 2017 . Effective January 1, 2018, under the new requirements of ASU 2016-01 , Recognition and Measurement of Financial Assets and Liabilities , we will recognize our unrealized holding gains and losses on our "available-for-sale" equity securities within "other (expense) income" on the Consolidated Statement of Operations (rather than through "other comprehensive income" on the Consolidated Statements of Comprehensive Loss). ** This note was reclassified to "other receivables" from "other assets" beginning March 31, 2017 due to its March 2018 maturity date
Schedule of Accounts Payable and Other Accrued Liabilities	“Accounts payable and other accrued liabilities” are comprised of the following : September 30, 2017 December 31, 2016 Trade accounts payable and other accrued liabilities $ 25,464 $ 30,488 Accrued rebates 8,120 8,350 Accrued product royalty 4,610 4,723 Allowance for returns 3,458 2,309 Accrued data and distribution fees 4,344 4,222 Accrued GPO administrative fees 449 384 Accrued inventory management fee 1,347 540 Allowance for chargebacks 1,843 1,467 Accounts payable and other accrued liabilities $ 49,635 $ 52,483
Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities	Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets for GTN estimates (see Note 2(i) ) were as follows: Rebates and Data and Returns Balance as of December 31, 2015 $ 20,167 $ 3,386 $ 1,394 Add: provisions 98,317 14,979 2,123 (Less): credits or actual allowances (108,667 ) (13,219 ) (1,208 ) Balance as of December 31, 2016 9,817 5,146 2,309 Add: provisions 85,602 15,495 2,164 (Less): credits or actual allowances (85,456 ) (14,501 ) (1,015 ) Balance as of September 30, 2017 $ 9,963 $ 6,140 $ 3,458
Deferred Revenue, by Arrangement, Disclosure	Deferred revenue (current and non-current) is comprised of the following: September 30, 2017 December 31, 2016 ZEVALIN out-license deferred revenue in Asia/other territories (see Note 11 ) $ — $ 1,255 EVOMELA deferred revenue* 2,731 1,887 ZEVALIN out-license in India territory (see Note 16(b)(iii) ) 376 369 Deferred revenue $ 3,107 $ 3,511 * We commercialized EVOMELA beginning in April 2016, and have deferred revenue recognition (see Note 2(i)(a) ) for any product shipped to our distributors, but not ordered and received by end-users as of September 30, 2017 and December 31, 2016 . This deferral is a result of our present inability to estimate future customer returns and rebate levels for this recently launched product
Summary of Other Long-Term Liabilities	"Other long-term liabilities" are comprised of the following: September 30, 2017 December 31, 2016 Accrued executive deferred compensation $ 10,250 $ 8,352 Deferred rent (non-current portion) 83 167 Clinical study holdbacks, non-current 56 47 Other tax liabilities 738 738 Royalty liability — 300 Other long-term liabilities $ 11,127 $ 9,604

Gross-to-Net Product Sales (Tab

Gross-to-Net Product Sales (Tables)	9 Months Ended
	Sep. 30, 2017
Revenue, Net [Abstract]
Reconciliation of Gross to Net Product Sales	The below table presents a GTN product sales reconciliation for the accompanying Condensed Consolidated Statements of Operations: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Gross product sales $ 66,517 $ 61,513 $ 192,443 $ 175,963 Commercial rebates and government chargebacks (28,075 ) (26,167 ) (85,400 ) (67,389 ) Data and distribution fees, GPO fees, and inventory management fees (5,864 ) (4,234 ) (15,503 ) (10,235 ) Prompt pay discounts (455 ) (300 ) (1,143 ) (380 ) Product returns allowance (889 ) (540 ) (2,162 ) (1,558 ) Product sales, net $ 31,234 $ 30,272 $ 88,235 $ 96,401

Composition of Total Revenue (T

Composition of Total Revenue (Tables)	9 Months Ended
	Sep. 30, 2017
Segment Reporting [Abstract]
Schedule of Product Sales, Net by Geography	The below table presents our net product sales by geography for the three and nine months ended September 30, 2017 and 2016 : Three Months Ended Nine Months Ended 2017 2016 2017 2016 United States $ 29,184 93.4 % $ 29,576 97.7 % $ 82,049 93.0 % $ 93,392 96.9 % Europe 2,050 6.6 % 696 2.3 % 6,186 7.0 % 3,009 3.1 % Product sales, net $ 31,234 100.0 % $ 30,272 100.0 % $ 88,235 100.0 % $ 96,401 100.0 %
Schedule Of Net Sales By Product Line	The below table presents our net product sales by drug for the three and nine months ended September 30, 2017 and 2016 : Three Months Ended Nine Months Ended 2017 2016 2017 2016 FUSILEV $ 1,792 5.7 % $ 4,893 16.2 % $ 6,426 7.3 % $ 30,568 31.7 % FOLOTYN 11,576 37.1 % 11,315 37.4 % 32,031 36.3 % 35,577 36.9 % ZEVALIN 2,737 8.8 % 2,627 8.7 % 7,881 8.9 % 8,224 8.5 % MARQIBO 1,227 3.9 % 1,925 6.4 % 5,369 6.1 % 4,921 5.1 % BELEODAQ 3,399 10.9 % 3,635 12.0 % 9,666 11.0 % 10,326 10.7 % EVOMELA 10,503 33.6 % 5,877 19.4 % 26,862 30.4 % 6,785 7.0 % Product sales, net $ 31,234 100.0 % $ 30,272 100.0 % $ 88,235 100.0 % $ 96,401 100.0 % The below table presents our license fees and service revenues by source for the three and nine months ended September 30, 2017 and 2016 : Three Months Ended Nine Months Ended 2017 2016 2017 2016 Sales and marketing contracted services ( Note 13 ) $ — — % $ 2,406 77.1 % $ 4,747 41.1 % $ 6,737 45.5 % Out-license of ZEVALIN, FOLOTYN, BELEODAQ, MARQIBO: upfront cash receipt and subsequent royalties for the Canada territory ( Note 16(b)(xv) ) — — % — — % 3 — % 6,000 40.5 % Out-license of ZEVALIN: recognition of upfront cash receipt and subsequent royalties for Asia and certain other territories, excluding China ( Note 11 ) — — % 474 15.2 % 1,245 10.8 % 1,308 8.8 % Out-license of FOLOTYN in all countries except the U.S., Canada, Europe, and Turkey: royalties ( Note 15 ) 5,148 99.7 % 229 7.3 % 5,530 47.8 % 705 4.8 % Out-license of ZEVALIN: amortization of upfront cash receipt related to India territory ( Note 16(b)(iii) ) and other 13 0.3 % 12 0.4 % 37 0.3 % 57 0.4 % License fees and service revenues $ 5,161 100.0 % $ 3,121 100.0 % $ 11,562 100.0 % $ 14,807 100.0 %

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Stock-Based Compensation Expense	Stock-based compensation expense included within “total operating costs and expenses” for the three and nine months ended September 30, 2017 and 2016 , was as follows: Three Months Ended Nine Months Ended 2017 2016 2017 2016 Cost of sales $ 68 $ 30 $ 150 $ 84 Research and development 592 470 1,438 1,461 Selling, general and administrative 2,750 2,650 8,066 8,209 Total stock-based compensation $ 3,410 $ 3,150 $ 9,654 $ 9,754

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2017
Earnings Per Share [Abstract]
Computation of Net Loss Per Share	Net loss per share was computed by dividing net loss by the weighted average number of common shares outstanding for the three and nine months ended September 30, 2017 and 2016 : Three Months Ended Nine Months Ended 2017 2016 2017 2016 Net loss $ (18,709 ) $ (17,455 ) $ (62,144 ) $ (51,070 ) Weighted average shares – basic and diluted 83,463,153 79,303,380 80,177,370 70,437,885 Net loss per share – basic and diluted $ (0.22 ) $ (0.22 ) $ (0.78 ) $ (0.73 )
Schedule of Securities Excluded from Calculation of Net Loss Per Share	The below outstanding securities were excluded from the above calculation of net loss per share because their impact under the "treasury stock method" and "if-converted method" would have been anti-dilutive due to our net loss per share in the three and nine months ended September 30, 2017 and 2016 , as summarized below: Three Months Ended Nine Months Ended 2017 2016 2017 2016 2018 Convertible Notes 10,454,799 11,401,284 10,454,799 11,401,284 Common stock options 3,144,969 1,603,028 1,504,155 1,498,034 Restricted stock awards 2,025,661 2,609,533 2,025,661 2,609,533 Common stock warrants 111,441 — 32,833 1,674 Preferred stock* — — — — Total 15,736,870 15,613,845 14,017,448 15,510,525 * In June 2016, our then 20 outstanding shares of Series E convertible voting preferred stock were converted (at the election of the preferred stockholders) into an aggregate of 40,000 common shares; a $6 thousand dividend in arrears was paid upon this conversion.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2017
Fair Value Disclosures [Abstract]
Summary of Asset and Liability Fair Values	The table below summarizes certain asset and liability fair values that are included within our accompanying Condensed Consolidated Balance Sheets, and their designations among three fair value measurement categories (see Note 2(xiii)) : September 30, 2017 Level 1 Level 2 Level 3 Total Assets: Bank certificates of deposits $ — $ 248 $ — $ 248 Money market funds — 225,894 — 225,894 Equity securities ( Note 10 ) 17,751 — — 17,751 Mutual funds — 58 — 58 Deferred compensation investments (life insurance cash surrender value) — 14,122 — 14,122 * $ 17,751 $ 240,322 $ — $ 258,073 Liabilities: Deferred executive compensation liability ( Note 16(f) ) $ — $ 10,250 $ — $ 10,250 * FOLOTYN development liability ( Note 15 ) — — 12,426 12,426 Talon CVR - MARQIBO ( Note 9(a) ) — — 4,489 4,489 Corixa Liability - ZEVALIN ( Note 16(b)(i) ) — — 62 62 $ — $ 10,250 $ 16,977 $ 27,227 December 31, 2016 Level 1 Level 2 Level 3 Total Assets: Bank certificates of deposits $ — $ 5,991 $ — $ 5,991 Money market funds — 128,563 — 128,563 Equity securities ( Note 10 ) 11,533 — — 11,533 Mutual funds — 56 — 56 Deferred compensation investments (life insurance cash surrender value) — 11,863 — 11,863 * $ 11,533 $ 146,473 $ — $ 158,006 Liabilities: Deferred executive compensation liability ( Note 16(f) ) $ — $ 8,352 $ — $ 8,352 * FOLOTYN development liability ( Note 15 ) — — 13,130 13,130 Talon CVR - MARQIBO ( Note 9(a) ) — — 1,253 1,253 Corixa Liability - ZEVALIN ( Note 16(b)(i) ) — — 62 62 $ — $ 8,352 $ 14,445 $ 22,797 * The reported value of "deferred compensation investments" is based on the cash surrender value of the life insurance policies, while the value of the "deferred executive compensation liability" is based on the market value of the underlying investment holdings.
Fair Value Measurement Activity for Liabilities Utilize Level 3 Inputs	The table below summarizes the 2016 and 2017 activity of our liabilities that are valued with unobservable inputs (i.e, "Level 3"): Fair Value Measurements of Balance at December 31, 2015 $ 21,352 Settlement of Ligand Contingent Consideration liability - EVOMELA (see Note 9(b) ) (6,000 ) FOLOTYN development liability (see Note 15 ) (1,556 ) Ligand Contingent Consideration fair value adjustment prior to settlement - EVOMELA (see Note 9(b) ) 773 Talon CVR fair value adjustment - MARQIBO (see Note 9(a) ) (124 ) Balance at December 31, 2016 14,445 FOLOTYN development liability (see Note 15 ) (704 ) Talon CVR fair value adjustment - MARQIBO (see Note 9(a) ) 3,236 Balance at September 30, 2017* $ 16,977 * This amount is comprised of the current and non-current portions of “FOLOTYN development liability” and the non-current portion of “acquisition-related contingent obligations” on our accompanying Condensed Consolidated Balance Sheets.

Business Combinations and Con34

Business Combinations and Contingent Consideration (Tables)	9 Months Ended
	Sep. 30, 2017
Talon Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Change in Fair Value of Contingent Consideration Related to Acquisitions	Fair Value December 31, 2016 $ 1,253 Fair value adjustment for the nine months ended September 30, 2017 3,236 September 30, 2017 $ 4,489
Acquisition-Date Fair Value of Consideration Transferred	The acquisition-date fair value of the consideration transferred consisted of the following: Cash consideration $ 3,000 Ligand Contingent Consideration 4,700 Total purchase consideration $ 7,700
Melphalan license [Member]
Business Acquisition [Line Items]
Change in Fair Value of Contingent Consideration Related to Acquisitions	Fair Value of December 31, 2015 $ 5,227 Fair value adjustment for the three months ended March 31, 2016 773 Payment to Ligand in April 2016 for FDA approval milestone achievement (6,000 ) December 31, 2016 $ —
Summary of Allocation of Total Purchase Price to Net Assets Acquired	The allocation of the total purchase price to the net assets acquired is as follows: EVOMELA distribution rights $ 7,700

Out-License of Marqibo, Zeval35

Out-License of Marqibo, Zevalin, and Evomela in China Territory (Tables)	9 Months Ended
	Sep. 30, 2017
Other Commitments [Abstract]
Schedule of Proceeds Received and Fair Value on CASI Out-License Execution Date	The proceeds we received, and its fair value on the CASI Out-License execution date, consisted of the following: CASI common stock (5.4 million shares) $ 8,649 (a) CASI secured promissory note due March 17, 2018, net of fair value discount ($1.5 million face value and 0.5% annual coupon) 1,310 (b) Total consideration received, net of fair value discount $ 9,959 (c) (a) Value determined based on the September 17, 2014 closing price of 5.4 million shares of CASI common stock on the NASDAQ Capital Market of $1.60 per share. Our current intention is to hold these securities on a long-term basis. Accordingly, we have presented its value of $17.8 million as of September 30, 2017 within "other assets" (rather than "marketable securities") on our accompanying Condensed Consolidated Balance Sheets. The change in fair value of these securities is reported within "other assets" and "accumulated deficit" (as a component of "other comprehensive income (loss)") within the accompanying Condensed Consolidated Balance Sheets (see Note 3(g) ). (b) Value estimated using the terms of the $1.5 million promissory note, the application of a synthetic debt rating based on CASI’s publicly-available financial information, and the prevailing interest yields on similar public debt securities as of September 17, 2014. This full balance was prospectively reclassified beginning March 31, 2017 to "other receivables" (presented within current assets on the accompanying Condensed Consolidated Balance Sheets) from "other assets" (presented within non-current assets) due to this note's maturity date of March 17, 2018 (i.e., within 12 months of March 31, 2017). (c) Presented within “license fees and service revenue” in the Consolidated Statements of Operations for the year ended December 31, 2015 (see below).

Convertible Senior Notes (Table

Convertible Senior Notes (Tables)	9 Months Ended
	Sep. 30, 2017
Debt Disclosure [Abstract]
Carrying Value of 2018 Convertible Notes	The carrying value of the 2018 Convertible Notes as of September 30, 2017 and December 31, 2016 , is summarized as follows: September 30, 2017 December 31, 2016 Principal amount $ 110,037 $ 110,037 (Less): Unamortized debt discount (amortized through December 2018) (7,410 ) (11,646 ) (Less): Debt issuance costs (857 ) (1,348 ) Carrying value $ 101,770 $ 97,043
Components of the Interest Expense Recognized	The following table sets forth the components of interest expense recognized in the accompanying Condensed Consolidated Statements of Operations for the 2018 Convertible Notes for the nine months ended September 30, 2017 and 2016 : Nine Months Ended 2017 2016 Contractual coupon interest expense $ 2,270 $ 2,475 Amortization of debt issuance costs 491 521 Accretion of debt discount 4,236 4,246 Total $ 6,997 $ 7,242 Effective interest rate 8.65 % 8.66 %

FOLOTYN License Agreement And37

FOLOTYN License Agreement And Development Liability (Tables)	9 Months Ended
	Sep. 30, 2017
Business Combinations [Abstract]
Schedule of Drug Development Liability Adjustments	FOLOTYN FOLOTYN FOLOTYN Balance at December 31, 2016 $ 861 $ 12,269 $ 13,130 Transfer from long-term to current in 2017 (4 ) 4 — (Less): Expenses incurred in 2017 (704 ) — (704 ) Balance at September 30, 2017 $ 153 $ 12,273 $ 12,426

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2017
Equity [Abstract]
Stock Issued	We sold and issued shares of our common stock under both the December 2015 and August 2017 ATM Agreements, as summarized in the following table: Description of Financing Transaction No. of Common Shares Issued Proceeds Received (Net of Broker Commissions and Fees ) Common shares issued pursuant to the December 2015 ATM Agreement between April 1, 2016 and September 30, 2016 (no shares issued in remainder of 2016) 10,890,915 $ 73,869 Common shares issued pursuant to the December 2015 ATM Agreement between July 1, 2017 and July 31, 2017 3,243,882 $ 23,745 Common shares issued pursuant to the August 2017 ATM Agreement between August 1, 2017 and September 30, 2017 9,314,250 $ 90,221

Description of Business, Basi39

Description of Business, Basis of Presentation, and Operating Segment - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2017Segmentproduct
Segment Reporting Information [Line Items]
Number of late stage development products	3
Number of reportable operating segment | Segment	1
Spectrum Pharma Canada [Member]
Segment Reporting Information [Line Items]
Ownership interest, percentage	50.00%
Cancer Drugs [Member]
Segment Reporting Information [Line Items]
Number of products for sale	6

Summary of Significant Accoun40

Summary of Significant Accounting Policies and Use of Estimates - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2017
Accounting Policies [Line Items]
Number of months customers are allowed to return products	6 months
Cash and equivalents maturities period	3 months
EVOMELA [Member]
Accounting Policies [Line Items]
Number of months customers are allowed to return products	12 months

Balance Sheet Account Detail -

Balance Sheet Account Detail - Summary of Cash and Cash Equivalents and Marketable Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Schedule of Investments [Line Items]
Cash and cash equivalents, marketable securities, cost	$ 247,716	$ 158,469
Cash and cash equivalents, marketable securities, gross unrealized gains	0	0
Cash and cash equivalents, marketable securities, gross unrealized losses	0	0
Cash and cash equivalents, marketable securities, estimated fair value	247,716	158,469
Cash and cash equivalents	247,468	158,222	$ 171,605	$ 139,741
Marketable security, current	248	247
Marketable securities, noncurrent	0	0
Bank Deposits [Member]
Schedule of Investments [Line Items]
Bank deposits, cost	21,574	23,915
Bank deposits, gross unrealized gains	0	0
Bank deposits, gross unrealized losses	0	0
Bank deposits, estimated fair value	21,574	23,915
Cash and cash equivalents	21,574	23,915
Marketable security, current	0	0
Marketable securities, noncurrent	0	0
Money market funds [Member]
Schedule of Investments [Line Items]
Marketable security, amortized cost	225,894	128,563
Marketable security, gross unrealized gains	0	0
Marketable security, gross unrealized losses	0	0
Marketable securities, fair value	225,894	128,563
Cash and cash equivalents	225,894	128,563
Marketable security, current	0	0
Marketable securities, noncurrent	0	0
Bank CDs [Member]
Schedule of Investments [Line Items]
Marketable security, amortized cost	248	5,991
Marketable security, gross unrealized gains	0	0
Marketable security, gross unrealized losses	0	0
Marketable securities, fair value	248	5,991
Cash and cash equivalents	0	5,744
Marketable security, current	248	247
Marketable securities, noncurrent	$ 0	$ 0

Balance Sheet Account Detail 42

Balance Sheet Account Detail - Schedule of Property and Equipment Net of Accumulated Depreciation (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 6,711	$ 6,295
(Less): Accumulated depreciation	(6,096)	(5,846)
Property and equipment, net of accumulated depreciation	615	449
Computer hardware and software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	2,933	2,550
Laboratory equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	622	622
Office furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	218	211
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$ 2,938	$ 2,912

Balance Sheet Account Detail 43

Balance Sheet Account Detail - Additional Information (Detail) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Schedule Of Investments In Marketable Securities [Line Items]
Securities in continuous unrealized loss position, period	longer than one year.
Depreciation expense	$ 0.2	$ 0.4
Other Intangible Assets [Member]
Schedule Of Investments In Marketable Securities [Line Items]
Intangible asset amortization expense	$ 20.7	$ 19.1

Balance Sheet Account Detail 44

Balance Sheet Account Detail - Components of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 1,683	$ 2,991
Work-in-process	7,457	7,838
Finished goods	3,439	2,305
(Less:) Non-current portion of inventories included within other assets	(3,596)	(4,419)
Inventories	$ 8,983	$ 8,715

Balance Sheet Account Detail 45

Balance Sheet Account Detail - Prepaid Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid insurance	$ 185	$ 721
Inventory other	712	1,458
Other miscellaneous prepaid operating expenses	2,060	1,751
Prepaid expenses and other assets	$ 2,957	$ 3,930

Balance Sheet Account Detail 46

Balance Sheet Account Detail - Schedule of Other Receivables (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
FOLOTYN milestone for first sale in Japan	$ 2,000	$ 0
CASI note - short term	1,515	0
Other miscellaneous receivables	1,033	239
Employee receivables	857	0
Reimbursements due from development partners for incurred research and development expenses	418	1,796
Insurance receivable	53	500
Receivable for contracted sales and marketing services	0	1,831
Income tax receivable	0	1,388
Other receivables	5,876	$ 5,754
Medicaid rebate credit	$ 600

Balance Sheet Account Detail 47

Balance Sheet Account Detail - Components of Intangible Assets Net of Accumulated Amortization (Detail) - USD ($) $ in Thousands	Mar. 10, 2016	Apr. 30, 2016	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2013	Sep. 30, 2017	Dec. 31, 2016
Product Rights [Line Items]
Historical Cost						$ 305,668	$ 305,668
Accumulated Amortization						(150,686)	(128,213)
Foreign Currency Translation						(2,763)	(5,038)
Impairment						(8,183)	(8,183)
Net Amount						144,036	164,234
Ligand Pharmaceuticals Inc [Member]
Product Rights [Line Items]
Milestone payments	$ 6,000	$ 6,000	$ 6,000
MARQIBO IPR&D (NHL indication) [Member]
Product Rights [Line Items]
Historical Cost						17,600	17,600
Accumulated Amortization						0	0
Foreign Currency Translation						0	0
Impairment						0	0
Net Amount						17,600	17,600
EVOMELA distribution rights [Member]
Product Rights [Line Items]
Historical Cost		$ 7,700				7,700	7,700
Accumulated Amortization						(888)	(444)
Foreign Currency Translation						0	0
Impairment						0	0
Net Amount						$ 6,812	7,256
Full Amortization Period (months)						156 months
Remaining Amortization Period (months)						138 months
BELEODAQ distribution rights [Member]
Product Rights [Line Items]
Historical Cost						$ 25,000	25,000
Accumulated Amortization						(6,094)	(4,688)
Foreign Currency Translation						0	0
Impairment						0	0
Net Amount						$ 18,906	20,312
Full Amortization Period (months)						160 months
Remaining Amortization Period (months)						121 months
MARQIBO distribution rights [Member]
Product Rights [Line Items]
Historical Cost						$ 26,900	26,900
Accumulated Amortization						(16,102)	(12,863)
Foreign Currency Translation						0	0
Impairment						0	0
Net Amount						$ 10,798	14,037
Full Amortization Period (months)						81 months
Remaining Amortization Period (months)						30 months
FOLOTYN distribution rights [Member]
Product Rights [Line Items]
Historical Cost						$ 118,400	118,400
Accumulated Amortization						(50,843)	(41,036)
Foreign Currency Translation						0	0
Impairment					$ (1,000)	0	0
Net Amount						$ 67,557	77,364
Full Amortization Period (months)						152 months
Remaining Amortization Period (months)						62 months
ZEVALIN distribution rights [Member] | United States [Member]
Product Rights [Line Items]
Historical Cost						$ 41,900	41,900
Accumulated Amortization						(36,688)	(34,083)
Foreign Currency Translation						0	0
Impairment						0	0
Net Amount						$ 5,212	7,817
Full Amortization Period (months)						123 months
Remaining Amortization Period (months)						18 months
ZEVALIN distribution rights [Member] | Ex-U.S. [Member]
Product Rights [Line Items]
Historical Cost						$ 23,490	23,490
Accumulated Amortization						(16,579)	(13,649)
Foreign Currency Translation						(2,763)	(5,038)
Impairment						0	0
Net Amount						$ 4,148	4,803
Full Amortization Period (months)						96 months
Remaining Amortization Period (months)						30 months
FUSILEV distribution rights [Member]
Product Rights [Line Items]
Historical Cost						$ 16,778	16,778
Accumulated Amortization						(9,618)	(9,618)
Foreign Currency Translation						0	0
Impairment						(7,160)	(7,160)
Net Amount						$ 0	0
Full Amortization Period (months)						56 months
Remaining Amortization Period (months)						0 months
FOLOTYN out-License [Member]
Product Rights [Line Items]
Historical Cost						$ 27,900	27,900
Accumulated Amortization						(13,874)	(11,832)
Foreign Currency Translation						0	0
Impairment						(1,023)	(1,023)
Net Amount						$ 13,003	$ 15,045
Full Amortization Period (months)						110 months
Remaining Amortization Period (months)						58 months
EVOMELA [Member]
Product Rights [Line Items]
Historical Cost			$ 7,700
FUSILEV [Member]
Product Rights [Line Items]
Impairment				$ (7,200)

Balance Sheet Account Detail 48

Balance Sheet Account Detail - Estimated Intangible Asset Amortization Expense (Detail) $ in Thousands	Sep. 30, 2017USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Remainder of 2017	$ 6,930
2,018	27,719
2,019	25,114
2,020	19,761
2,021	18,266
2,022	15,882
2023 and thereafter	12,764
Intangible Assets, Net Total	$ 126,436

Balance Sheet Account Detail 49

Balance Sheet Account Detail - Schedule of Goodwill (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Goodwill [Line Items]
Foreign currency exchange translation effects	$ (266)	$ (511)
Goodwill	18,131	17,886
ZEVALIN Ex-U.S. Distribution Rights [Member]
Goodwill [Line Items]
Acquisition	2,525	2,525
Allos Therapeutics, Inc. [Member]
Goodwill [Line Items]
Acquisition	5,346	5,346
Talon [Member]
Goodwill [Line Items]
Acquisition	$ 10,526	$ 10,526

Balance Sheet Account Detail 50

Balance Sheet Account Detail - Summary of Other Assets (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Equity securities (see Note 10)	$ 17,751	$ 11,533
Promissory note receivable - long term	0	1,510
Research & development supplies and other	267	224
Executive officer life insurance – cash surrender value	14,122	11,863
Inventories - non-current portion	3,596	4,419
Other assets	35,736	$ 29,549
Unrealized gain (loss)	$ 3,900

Balance Sheet Account Detail 51

Balance Sheet Account Detail - Schedule of Accounts Payable and Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Trade accounts payable and other accrued liabilities	$ 25,464	$ 30,488
Accrued rebates	8,120	8,350
Accrued product royalty	4,610	4,723
Allowance for returns	3,458	2,309
Accrued data and distribution fees	4,344	4,222
Accrued GPO administrative fees	449	384
Accrued inventory management fee	1,347	540
Allowance for chargebacks	1,843	1,467
Accounts payable and other accrued liabilities	$ 49,635	$ 52,483

Balance Sheet Account Detail 52

Balance Sheet Account Detail - Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Rebates and Chargebacks [Member]
Accounts Payable and Other Liabilities [Roll Forward]
Beginning balance	$ 9,817	$ 20,167
Add: provisions	85,602	98,317
(Less): credits or actual allowances	(85,456)	(108,667)
Ending balance	9,963	9,817
Data and Distribution, GPO Fees, and Inventory Management Fees [Member]
Accounts Payable and Other Liabilities [Roll Forward]
Beginning balance	5,146	3,386
Add: provisions	15,495	14,979
(Less): credits or actual allowances	(14,501)	(13,219)
Ending balance	6,140	5,146
Returns [Member]
Accounts Payable and Other Liabilities [Roll Forward]
Beginning balance	2,309	1,394
Add: provisions	2,164	2,123
(Less): credits or actual allowances	(1,015)	(1,208)
Ending balance	$ 3,458	$ 2,309

Balance Sheet Account Detail 53

Balance Sheet Account Detail - Deferred Revenue (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 3,107	$ 3,511
Dr. Reddy [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	376	369
ZEVALIN Out-License [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	0	1,255
EVOMELA [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 2,731	$ 1,887

Balance Sheet Account Detail 54

Balance Sheet Account Detail - Summary of Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued executive deferred compensation	$ 10,250	$ 8,352
Deferred rent (non-current portion)	83	167
Clinical study holdbacks, non-current	56	47
Other tax liabilities	738	738
Royalty liability	0	300
Other long-term liabilities	$ 11,127	$ 9,604

Gross-to-Net Product Sales - Re

Gross-to-Net Product Sales - Reconciliation of Gross-to-Net Product Sales (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenue, Net [Abstract]
Gross product sales	$ 66,517	$ 61,513	$ 192,443	$ 175,963
Commercial rebates and government chargebacks	(28,075)	(26,167)	(85,400)	(67,389)
Data and distribution fees, GPO fees, and inventory management fees	(5,864)	(4,234)	(15,503)	(10,235)
Prompt pay discounts	(455)	(300)	(1,143)	(380)
Product returns allowance	(889)	(540)	(2,162)	(1,558)
Product sales, net	$ 31,234	$ 30,272	$ 88,235	$ 96,401

Composition of Total Revenue -

Composition of Total Revenue - Schedule of Product Sales, Net by Geography (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Product sales, net	$ 31,234	$ 30,272	$ 88,235	$ 96,401
Percentage of product sales, net	100.00%	100.00%	100.00%	100.00%
United States [Member]
Segment Reporting Information [Line Items]
Product sales, net	$ 29,184	$ 29,576	$ 82,049	$ 93,392
Percentage of product sales, net	93.40%	97.70%	93.00%	96.90%
Europe (ZEVALIN only) [Member]
Segment Reporting Information [Line Items]
Product sales, net	$ 2,050	$ 696	$ 6,186	$ 3,009
Percentage of product sales, net	6.60%	2.30%	7.00%	3.10%

Composition of Total Revenue 57

Composition of Total Revenue - Schedule of Product Sales, Net by Product Line (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Segment Reporting Information [Line Items]
Product sales, net	$ 31,234	$ 30,272	$ 88,235	$ 96,401
Percentage of product sales, net	100.00%	100.00%	100.00%	100.00%
FUSILEV [Member]
Segment Reporting Information [Line Items]
Product sales, net	$ 1,792	$ 4,893	$ 6,426	$ 30,568
FOLOTYN [Member]
Segment Reporting Information [Line Items]
Product sales, net	11,576	11,315	32,031	35,577
ZEVALIN [Member]
Segment Reporting Information [Line Items]
Product sales, net	2,737	2,627	7,881	8,224
MARQIBO [Member]
Segment Reporting Information [Line Items]
Product sales, net	1,227	1,925	5,369	4,921
BELEODAQ [Member]
Segment Reporting Information [Line Items]
Product sales, net	3,399	3,635	9,666	10,326
EVOMELA [Member]
Segment Reporting Information [Line Items]
Product sales, net	$ 10,503	$ 5,877	$ 26,862	$ 6,785
Sales [Member]
Segment Reporting Information [Line Items]
Percentage of product sales, net	100.00%	100.00%	100.00%	100.00%
Sales [Member] | FUSILEV [Member]
Segment Reporting Information [Line Items]
Percentage of product sales, net	5.70%	16.20%	7.30%	31.70%
Sales [Member] | FOLOTYN [Member]
Segment Reporting Information [Line Items]
Percentage of product sales, net	37.10%	37.40%	36.30%	36.90%
Sales [Member] | ZEVALIN [Member]
Segment Reporting Information [Line Items]
Percentage of product sales, net	8.80%	8.70%	8.90%	8.50%
Sales [Member] | MARQIBO [Member]
Segment Reporting Information [Line Items]
Percentage of product sales, net	3.90%	6.40%	6.10%	5.10%
Sales [Member] | BELEODAQ [Member]
Segment Reporting Information [Line Items]
Percentage of product sales, net	10.90%	12.00%	11.00%	10.70%
Sales [Member] | EVOMELA [Member]
Segment Reporting Information [Line Items]
Percentage of product sales, net	33.60%	19.40%	30.40%	7.00%

Composition of Total Revenue 58

Composition of Total Revenue - By Product Line (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Concentration Risk [Line Items]
License fees and service revenue	$ 5,161	$ 3,121	$ 11,562	$ 14,807
License fees and service revenues (percent)	100.00%	100.00%	100.00%	100.00%
Sales Revenue, Services, Net [Member]
Concentration Risk [Line Items]
License fees and service revenues (percent)	100.00%	100.00%	100.00%	100.00%
Sales and marketing contracted services [Member]
Concentration Risk [Line Items]
License fees and service revenue	$ 0	$ 2,406	$ 4,747	$ 6,737
Sales and marketing contracted services [Member] | Sales Revenue, Services, Net [Member]
Concentration Risk [Line Items]
License fees and service revenues (percent)	0.00%	77.10%	41.10%	45.50%
Out-license of ZEVALIN, FOLOTYN, BELEODAQ, MARQIBO: upfront cash receipt and subsequent royalties for the Canada territory [Member]
Concentration Risk [Line Items]
License fees and service revenue	$ 0	$ 0	$ 3	$ 6,000
Out-license of ZEVALIN, FOLOTYN, BELEODAQ, MARQIBO: upfront cash receipt and subsequent royalties for the Canada territory [Member] | Sales Revenue, Services, Net [Member]
Concentration Risk [Line Items]
License fees and service revenues (percent)	0.00%	0.00%	0.00%	40.50%
Out-license of ZEVALIN: recognition of upfront cash receipt and subsequent royalties for Asia and certain other territories, excluding China [Member]
Concentration Risk [Line Items]
License fees and service revenue	$ 0	$ 474	$ 1,245	$ 1,308
Out-license of ZEVALIN: recognition of upfront cash receipt and subsequent royalties for Asia and certain other territories, excluding China [Member] | Sales Revenue, Services, Net [Member]
Concentration Risk [Line Items]
License fees and service revenues (percent)	0.00%	15.20%	10.80%	8.80%
Out-license of FOLOTYN [Member]
Concentration Risk [Line Items]
License fees and service revenue	$ 5,148	$ 229	$ 5,530	$ 705
Out-license of FOLOTYN [Member] | Sales Revenue, Services, Net [Member]
Concentration Risk [Line Items]
License fees and service revenues (percent)	99.70%	7.30%	47.80%	4.80%
Out-license of ZEVALIN: amortization of upfront cash receipt related to India territory and other [Member]
Concentration Risk [Line Items]
License fees and service revenue	$ 13	$ 12	$ 37	$ 57
Out-license of ZEVALIN: amortization of upfront cash receipt related to India territory and other [Member] | Sales Revenue, Services, Net [Member]
Concentration Risk [Line Items]
License fees and service revenues (percent)	0.30%	0.40%	0.30%	0.40%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ 3,410	$ 3,150	$ 9,654	$ 9,754
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	68	30	150	84
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	592	470	1,438	1,461
Selling, general and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation	$ 2,750	$ 2,650	$ 8,066	$ 8,209

Net Loss Per Share - Computatio

Net Loss Per Share - Computation of Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Earnings Per Share [Abstract]
Net loss	$ (18,709)	$ (17,455)	$ (62,144)	$ (51,070)
Weighted average shares - basic and diluted (shares)	83,463,153	79,303,380	80,177,370	70,437,885
Net loss per share - basic and diluted ($ per share)	$ (0.22)	$ (0.22)	$ (0.78)	$ (0.73)

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Securities Excluded from Calculation of Net Loss Per Share (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)		15,736,870	15,613,845	14,017,448	15,510,525
Preferred stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)		0	0	0	0
2018 Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)		10,454,799	11,401,284	10,454,799	11,401,284
Common stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)		3,144,969	1,603,028	1,504,155	1,498,034
Restricted stock awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)		2,025,661	2,609,533	2,025,661	2,609,533
Series E Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Conversion rate, shares (shares)	20
Issued in conversion (shares)	40,000
Dividends in arrears	$ 6
Common Stock Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive excluded from computation of earnings per share amount (shares)		111,441	0	32,833	1,674

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Asset and Liability Fair Values (Detail) - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Assets:
Deferred compensation investments (life insurance cash surrender value)	$ 14,122	$ 11,863
Total Assets	258,073	158,006
Liabilities:
Deferred executive compensation liability (Note 16(f))	10,250	8,352
FOLOTYN development liability (Note 15)	12,426	13,130
Talon CVR - MARQIBO (Note 9(a))	4,489	1,253
Corixa Liability - ZEVALIN (Note 16(b)(i))	62	62
Total Liabilities	27,227	22,797
Bank CDs [Member]
Assets:
Marketable securities, fair value	248	5,991
Money market currency funds [Member]
Assets:
Marketable securities, fair value	225,894	128,563
Equity Securities [Member]
Assets:
Marketable securities, fair value	17,751	11,533
Mutual Funds [Member]
Assets:
Marketable securities, fair value	58	56
Level 1 [Member]
Assets:
Deferred compensation investments (life insurance cash surrender value)	0	0
Total Assets	17,751	11,533
Liabilities:
Deferred executive compensation liability (Note 16(f))	0	0
FOLOTYN development liability (Note 15)	0	0
Talon CVR - MARQIBO (Note 9(a))	0	0
Corixa Liability - ZEVALIN (Note 16(b)(i))	0	0
Total Liabilities	0	0
Level 1 [Member] | Bank CDs [Member]
Assets:
Marketable securities, fair value	0	0
Level 1 [Member] | Money market currency funds [Member]
Assets:
Marketable securities, fair value	0	0
Level 1 [Member] | Equity Securities [Member]
Assets:
Marketable securities, fair value	17,751	11,533
Level 1 [Member] | Mutual Funds [Member]
Assets:
Marketable securities, fair value	0	0
Level 2 [Member]
Assets:
Deferred compensation investments (life insurance cash surrender value)	14,122	11,863
Total Assets	240,322	146,473
Liabilities:
Deferred executive compensation liability (Note 16(f))	10,250	8,352
FOLOTYN development liability (Note 15)	0	0
Talon CVR - MARQIBO (Note 9(a))	0	0
Corixa Liability - ZEVALIN (Note 16(b)(i))	0	0
Total Liabilities	10,250	8,352
Level 2 [Member] | Bank CDs [Member]
Assets:
Marketable securities, fair value	248	5,991
Level 2 [Member] | Money market currency funds [Member]
Assets:
Marketable securities, fair value	225,894	128,563
Level 2 [Member] | Equity Securities [Member]
Assets:
Marketable securities, fair value	0	0
Level 2 [Member] | Mutual Funds [Member]
Assets:
Marketable securities, fair value	58	56
Level 3 [Member]
Assets:
Deferred compensation investments (life insurance cash surrender value)	0	0
Total Assets	0	0
Liabilities:
Deferred executive compensation liability (Note 16(f))	0	0
FOLOTYN development liability (Note 15)	12,426	13,130
Talon CVR - MARQIBO (Note 9(a))	4,489	1,253
Corixa Liability - ZEVALIN (Note 16(b)(i))	62	62
Total Liabilities	16,977	14,445
Level 3 [Member] | Bank CDs [Member]
Assets:
Marketable securities, fair value	0	0
Level 3 [Member] | Money market currency funds [Member]
Assets:
Marketable securities, fair value	0	0
Level 3 [Member] | Equity Securities [Member]
Assets:
Marketable securities, fair value	0	0
Level 3 [Member] | Mutual Funds [Member]
Assets:
Marketable securities, fair value	$ 0	$ 0

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value Measurement Activity for Liabilities Utilize Level 3 Inputs (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning	$ 14,445	$ 21,352
Settlement of Ligand Contingent Consideration liability - EVOMELA (see Note 9(b))		(6,000)
Ending	16,977	14,445
FOLOTYN development liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Increase/decrease	(704)	(1,556)
Ligand Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Increase/decrease		773
Talon CVR [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Increase/decrease	$ 3,236	$ (124)

Business Combinations and Con64

Business Combinations and Contingent Consideration - Additional Information (Detail) - USD ($) $ / shares in Units, shares in Millions	Mar. 10, 2016	Jul. 17, 2013	Sep. 05, 2012	Apr. 30, 2016	Mar. 31, 2016	Mar. 31, 2013	Mar. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
License fees received						$ 3,000,000
Historical Cost								$ 305,668,000		$ 305,668,000
Acquisition related contingent obligations								0	$ (1,300,000)
In-process research and development [Member]
Business Acquisition [Line Items]
Estimated cash flow period						10 years
Estimated cash flow discount rate						25.00%
Ligand Pharmaceuticals Inc [Member]
Business Acquisition [Line Items]
Milestone payments	$ 6,000,000			$ 6,000,000	$ 6,000,000
Melphalan In Process Research and Development [Member]
Business Acquisition [Line Items]
Historical Cost				$ 7,700,000				$ 7,700,000		$ 7,700,000
Minimum [Member]
Business Acquisition [Line Items]
Royalties payout percentage on our future net sales of licensed products								20.00%
Milestone Payments [Member]
Business Acquisition [Line Items]
Milestone payments		$ 5,000,000						$ 60,000,000
Milestone net sales achievement		30,000,000
Ligand Contingent Consideration					6,000,000		$ 6,000,000
Milestone Payment One [Member]
Business Acquisition [Line Items]
Milestone payments		10,000,000
Milestone net sales achievement		60,000,000
Milestone Payment Two [Member]
Business Acquisition [Line Items]
Milestone payments		25,000,000
Milestone net sales achievement		100,000,000
Milestone Payment Three [Member]
Business Acquisition [Line Items]
Milestone payments		50,000,000
Milestone net sales achievement		200,000,000
Milestone Payment Four [Member]
Business Acquisition [Line Items]
Milestone payments		100,000,000
Milestone net sales achievement		400,000,000
Menadione Topical Lotion [Member]
Business Acquisition [Line Items]
Milestone payments		5,000,000
Talon Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Additional shares business acquisition date								Jul. 17, 2013
Cash consideration		$ 11,300,000
Shares issued in acquisition (shares)		3
Common stock value assigned		$ 26,300,000
Common stock value, per share ($ per share)		$ 8.77
Estimated fair value of acquisition		$ 6,500,000
Contingent value rights future cash payments		$ 195,000,000						$ 195,000,000
Talon Therapeutics, Inc. [Member] | Minimum [Member]
Business Acquisition [Line Items]
Contingent value rights expected rate		50.00%
Talon Therapeutics, Inc. [Member] | Maximum [Member]
Business Acquisition [Line Items]
Contingent value rights expected rate		100.00%
Ligand Pharmaceuticals Inc [Member]
Business Acquisition [Line Items]
Ligand Contingent Consideration					$ 6,000,000		6,000,000
Acquisition related contingent obligations							$ 800,000
Allos Therapeutics, Inc. [Member]
Business Acquisition [Line Items]
Cash consideration			$ 205,200,000

Business Combinations and Con65

Business Combinations and Contingent Consideration - Change in Fair Value of Contingent Consideration Related to Acquisitions (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2017	Dec. 31, 2016
Change in Fair Value of Contingent Consideration [Roll Forward]
Beginning	$ 14,445	$ 21,352
Ending	16,977	14,445
Contingent Consideration [Member] | Talon Therapeutics, Inc. [Member]
Change in Fair Value of Contingent Consideration [Roll Forward]
Beginning	1,253
Fair value adjustment for the nine months ended September 30, 2017	3,236
Ending	4,489	1,253
Contingent Consideration [Member] | Ligand Pharmaceuticals Inc [Member]
Change in Fair Value of Contingent Consideration [Roll Forward]
Beginning	$ 0	5,227
Fair value adjustment for the nine months ended September 30, 2017		773
Payment to Ligand in April 2016 for FDA approval milestone achievement		(6,000)
Ending		$ 0

Business Combinations and Con66

Business Combinations and Contingent Consideration - Acquisition-Date Fair Value of Consideration Transferred (Detail) - Captisol-enabled, propylene glycol-free melphalan rights [Member] $ in Thousands	1 Months Ended
	Mar. 31, 2013USD ($)
Business Acquisition [Line Items]
Cash consideration	$ 3,000
Ligand Contingent Consideration	4,700
Total purchase consideration	$ 7,700

Business Combinations and Con67

Business Combinations and Contingent Consideration - Summary of Allocation of Total Purchase Price to Net Assets Acquired (Detail) - Captisol-enabled, propylene glycol-free melphalan rights [Member] $ in Thousands	Mar. 31, 2013USD ($)
Business Acquisition, Contingent Consideration [Line Items]
Total purchase consideration	$ 7,700
In-process research and development [Member]
Business Acquisition, Contingent Consideration [Line Items]
Total purchase consideration	$ 7,700

Out-License of Marqibo, Zeval68

Out-License of Marqibo, Zevalin, and Evomela in China Territory - Additional Information (Detail) - CASI Out-License [Member] shares in Millions, $ in Millions	Sep. 17, 2014USD ($)productagreementshares	Sep. 30, 2017shares	Dec. 31, 2016shares
Other Commitments [Line Items]
Number of agreements | agreement	3
Number of products | product	2
License agreement description		Additionally, under certain conditions which generally expire on September 17, 2019, we have a right to receive additional CASI common stock in order to maintain our post-investment ownership percentage if CASI issues additional securities.
Shares received (shares) | shares	5.4	10	4.6
Undiscounted proceeds | $	$ 9.7

Out-License of Marqibo, Zeval69

Out-License of Marqibo, Zevalin, and Evomela in China Territory - Schedule of Proceeds Received and Fair Value on CASI Out-License Execution Date (Detail) - USD ($) $ / shares in Units, shares in Millions	Sep. 17, 2014	Sep. 30, 2017	Dec. 31, 2016
Other Commitments [Line Items]
Fair value		$ 17,751,000	$ 11,533,000
Secured Promissory Note Due March 17, 2016 [Member]
Other Commitments [Line Items]
Debt instrument face value	$ 1,500,000
CASI Out-License [Member]
Other Commitments [Line Items]
Total consideration received	$ 9,959,000
Shares received (shares)	5.4	10	4.6
Share price ($ per share)	$ 1.6
CASI Out-License [Member] | Secured Promissory Note Due March 17, 2016 [Member]
Other Commitments [Line Items]
Total consideration received	$ 1,310,000
Debt instrument coupon rate	0.50%
CASI Out-License [Member] | Common Stock [Member]
Other Commitments [Line Items]
Total consideration received	$ 8,649,000
Fair value		$ 17,800,000

Out-License Of Zevalin In Cer70

Out-License Of Zevalin In Certain Ex-U.S. Territories (Detail) - Zevalin Rights [Member] - USD ($) $ in Millions	Nov. 16, 2015	Jan. 31, 2016	Dec. 31, 2015	Nov. 30, 2015	Sep. 30, 2016	Dec. 31, 2015	Jun. 30, 2017	Sep. 30, 2017	Sep. 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential payment	$ 2			$ 2
Total Consideration [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total consideration received	$ 18			$ 18
Milestone net sales achievement						$ 15
Payment One [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total consideration received			$ 15
Payment Two [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total consideration received		$ 3
Milestone net sales achievement					$ 0.5		$ 3	$ 1.2	$ 1.3

Out-License Of Zevalin, Folot71

Out-License Of Zevalin, Folotyn, Beleodaq, And Marqibo In Canada Territory (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2016USD ($)
ZEVALIN, FOLOTYN, BELEODAQ, And MARQIBO [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Total consideration received	$ 6

Co-Promotion Arrangement With72

Co-Promotion Arrangement With Eagle Pharmaceuticals (Detail) $ in Thousands	Nov. 04, 2015USD ($)product	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License fees and service revenue		$ 5,161	$ 3,121	$ 11,562	$ 14,807
Collaborative Arrangement, Co-promotion [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Number of products | product	6
Fixed payment	$ 12,800
Term of contract	18 months
Reimbursable expense		0	2,200	4,200	5,700
Co-Promotion With Eagle [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License fees and service revenue		$ 0	$ 2,406	$ 4,747	$ 6,737

Convertible Senior Notes - Addi

Convertible Senior Notes - Additional Information (Detail)	Dec. 23, 2013USD ($)	Dec. 17, 2013USD ($)note	Dec. 31, 2016USD ($)open_market_purchaseshares	Sep. 30, 2017USD ($)day$ / sharesshares	Dec. 31, 2016USD ($)
Debt Disclosure [Line Items]
Common shares sold (shares)			$ 80,000	$ 94,000	$ 80,000
2.75% Convertible Senior Notes Due 2018 [Member]
Debt Disclosure [Line Items]
Sale of convertible notes, principal amount		$ 120,000,000
Interest rate		2.75%		2.75%
Number of notes if converted | note		120,000
Conversion rate, shares (shares) | shares				95
Value of principal units | $ / shares				$ 1,000
Common shares converted value (shares)				$ 11,400,000
Money conversion price per share ($ per share) | $ / shares				$ 10.53
Net proceeds from convertible notes	$ 115,400,000
Professional fee	4,600,000
Additional paid-in capital	$ 13,100,000
Number of open market purchases | open_market_purchase			2
Number of instruments | shares			9,963
Repurchase of principal			$ 10,000,000
Repayments			9,000,000
Gain (loss) on retirement					(25,000)
Debt instrument face value				$ 110,000,000
Proceeds from unwinding			21,000
Strike price per share ($ per share) | $ / shares				$ 14.03
Common shares sold (shares)				$ 11,400,000
Threshold percentage of conversion price				130.00%
Convertible senior notes trading price				$ 1,000
Percentage of product of last reported sale price of common stock				98.00%
Convertible senior notes conversion description				Prior to June 15, 2018, holders may convert all or a portion of their 2018 Convertible Notes only under any of the following circumstances: (1) during any fiscal quarter (and only during such fiscal quarter), if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of our common stock on such trading day is greater than or equal to 130% of the Notes' conversion price on such trading day; (2) during the five consecutive business day period immediately following any five consecutive trading day period in which, for each trading day of that measurement period, the trading price per $1,000 principal amount of 2018 Convertible Notes for such trading day was less than 98% of the product of (i) the last reported sale price of our common stock on such trading day and (ii) the applicable conversion rate on such trading day; (3) upon the occurrence of certain corporate transactions; and (4) at any time prior to our stockholders’ approval to settle the 2018 Convertible Notes in our common shares and/or cash.
2.75% Convertible Senior Notes Due 2018 [Member] | Minimum [Member]
Debt Disclosure [Line Items]
Debt convertible trading days				20 days
Debt convertible consecutive trading days | day				5
Debt convertible trading days | day				5
2.75% Convertible Senior Notes Due 2018 [Member] | Maximum [Member]
Debt Disclosure [Line Items]
Debt convertible consecutive trading days | day				30
2018 Convertible Notes [Member]
Debt Disclosure [Line Items]
Principal			110,037,000	$ 110,037,000	110,037,000
Fair value			$ 101,800,000	$ 156,400,000	$ 101,800,000

Convertible Senior Notes - Carr

Convertible Senior Notes - Carrying Value of 2018 Convertible Notes (Detail) - 2018 Convertible Notes [Member] - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Principal amount	$ 110,037	$ 110,037
(Less): Unamortized debt discount (amortized through December 2018)	(7,410)	(11,646)
(Less): Debt issuance costs	(857)	(1,348)
Carrying value	$ 101,770	$ 97,043

Convertible Senior Notes - Comp

Convertible Senior Notes - Components of the Interest Expense Recognized (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
Debt Disclosure [Abstract]
Contractual coupon interest expense	$ 2,270	$ 2,475
Amortization of debt issuance costs	491	521
Accretion of debt discount	4,236	4,246
Total	$ 6,997	$ 7,242
Effective interest rate	8.65%	8.66%

FOLOTYN License Agreement And76

FOLOTYN License Agreement And Development Liability - Additional Information (Detail) - USD ($) $ in Thousands	May 29, 2013	Sep. 30, 2012	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Company determined development payment			$ 51,865	$ 49,389	$ 154,822	$ 155,567
Mundipharma [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Company determined development payment	$ 7,000
Maximum [Member] | Regulatory [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments		$ 16,000			16,000
Maximum [Member] | Commercial Progress And Sales Dependent [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments		$ 107,000			$ 107,000

FOLOTYN License Agreement And77

FOLOTYN License Agreement And Development Liability - Schedule of Drug Development Liability Adjustments (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2017USD ($)
Accrued Drug Development Expenses [Roll Forward]
Balance at December 31, 2016	$ 861
Balance at September 30, 2017	153
FOLOTYN [Member]
Accrued Drug Development Expenses [Roll Forward]
Balance at December 31, 2016	13,130
Transfer from long-term to current in 2017	0
(Less): Expenses incurred in 2017	(704)
Balance at September 30, 2017	12,426
FOLOTYN [Member] | Development Liability, Current [Member]
Accrued Drug Development Expenses [Roll Forward]
Balance at December 31, 2016	861
Transfer from long-term to current in 2017	(4)
(Less): Expenses incurred in 2017	(704)
Balance at September 30, 2017	153
FOLOTYN [Member] | Development Liability, Long Term [Member]
Accrued Drug Development Expenses [Roll Forward]
Balance at December 31, 2016	12,269
Transfer from long-term to current in 2017	4
(Less): Expenses incurred in 2017	0
Balance at September 30, 2017	$ 12,273

Financial Commitments & Conti78

Financial Commitments & Contingencies and License Agreements - Additional Information (Detail) € in Millions	Mar. 10, 2016USD ($)	Nov. 16, 2015USD ($)	Sep. 30, 2017USD ($)	Aug. 31, 2017USD ($)	Jul. 31, 2017USD ($)shares	Apr. 30, 2016USD ($)shares	Mar. 31, 2016USD ($)shares	Feb. 29, 2016	Jan. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Nov. 30, 2015USD ($)	Feb. 28, 2015USD ($)	Jun. 30, 2014	Feb. 28, 2014USD ($)shares	Sep. 30, 2012USD ($)	Apr. 30, 2012EUR (€)	Feb. 28, 2010USD ($)	Nov. 30, 2009USD ($)	Oct. 31, 2008USD ($)	Dec. 31, 2002USD ($)	Sep. 30, 2017USD ($)shares	Sep. 30, 2016USD ($)	Mar. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Mar. 31, 2014USD ($)	Jun. 30, 2017USD ($)	Sep. 30, 2016USD ($)shares	Sep. 30, 2017USD ($)Country	Sep. 30, 2016USD ($)	Dec. 31, 2016USD ($)	Jul. 31, 2014USD ($)	Jul. 17, 2013USD ($)	May 31, 2006USD ($)
Long-term Purchase Commitment [Line Items]
Potential milestone achievement			$ 100,000																		$ 100,000							$ 100,000		$ 100,000
FOLOTYN milestone for first sale in Japan			2,000,000																		2,000,000							2,000,000		0
Amount receivable on approval of oral form of FUSILEV																																	$ 200,000
Additional license fees																												60,000,000
Acquisition-related contingent obligations			4,551,000																		$ 4,551,000							4,551,000		1,315,000
Common stock issued (shares) | shares					3,243,882																9,314,250						10,890,915
Upfront fee			2,600,000
Consideration paid for the rights granted (shares) | shares														1,000,000
Proceeds from issuance of common stock					$ 23,745,000																$ 90,221,000						$ 73,869,000	113,966,000	$ 73,869,000
Cash paid for income taxes																												10,000	11,000
Deferrals and contributions			10,300,000																		10,300,000							10,300,000		8,400,000
FOLOTYN [Member]
Long-term Purchase Commitment [Line Items]
Percentage of royalty on annual worldwide sales under condition one																				8.00%
Percentage of royalty on annual worldwide sales under condition two																				9.00%
Percentage of royalty on annual worldwide sales under condition three																				11.00%
Zevalin Rights [Member]
Long-term Purchase Commitment [Line Items]
Potential payment		$ 2,000,000									$ 2,000,000
ZEVALIN, FOLOTYN, BELEODAQ, And MARQIBO [Member]
Long-term Purchase Commitment [Line Items]
Total consideration received																							$ 6,000,000
Potential payment																												2,000,000
Total Consideration [Member] | Zevalin Rights [Member]
Long-term Purchase Commitment [Line Items]
Total consideration received		$ 18,000,000									$ 18,000,000
Milestone net sales achievement																								$ 15,000,000
Payment One [Member] | Zevalin Rights [Member]
Long-term Purchase Commitment [Line Items]
Total consideration received										$ 15,000,000
Payment Two [Member] | Zevalin Rights [Member]
Long-term Purchase Commitment [Line Items]
Total consideration received									$ 3,000,000
Milestone net sales achievement																						$ 500,000				$ 3,000,000		1,200,000	$ 1,300,000
Regulatory [Member]
Long-term Purchase Commitment [Line Items]
FOLOTYN milestone for first sale in Japan			2,000,000																		2,000,000							2,000,000
Ligand Pharmaceuticals Inc [Member]
Long-term Purchase Commitment [Line Items]
Milestone payments	$ 6,000,000					$ 6,000,000	$ 6,000,000
ZEVALIN [Member]
Long-term Purchase Commitment [Line Items]
Milestone payments																												$ 5,000,000
ZEVALIN [Member] | Licensing Agreements [Member]
Long-term Purchase Commitment [Line Items]
Fees paid to Bayer for acquiring licensing rights | €																€ 19
Minimum number of countries outside U.S. approved ZEVALIN for treatment | Country																												40
Percentage of royalty								20.00%
License agreement contractual terms								15 years
Talon Therapeutics, Inc. [Member]
Long-term Purchase Commitment [Line Items]
Acquisition-related contingent obligations			4,500,000																		4,500,000							$ 4,500,000		$ 1,300,000
Contingent value rights future cash payments			195,000,000																		195,000,000							195,000,000				$ 195,000,000
SPI-2012 [Member]
Long-term Purchase Commitment [Line Items]
Milestone payments						$ 2,700,000
Potential milestone achievement			225,000,000																		225,000,000							225,000,000
Payment on regulatory milestones			13,000,000																		13,000,000							13,000,000
Issuance (shares) | shares						318,750
Proceeds from issuance of common stock						$ 2,300,000
Cash paid for income taxes						$ 400,000
Poziotinib [Member] | Licensing Agreements [Member]
Long-term Purchase Commitment [Line Items]
Milestone net sales achievement																												325,000,000
Payment on regulatory milestones			$ 33,000,000																		$ 33,000,000							$ 33,000,000
Minimum [Member]
Long-term Purchase Commitment [Line Items]
Percentage of royalty on annual worldwide sales under condition one			20.00%																		20.00%							20.00%
Percentage of royalties on net sale of licensed products																												20.00%
Minimum [Member] | FOLOTYN [Member]
Long-term Purchase Commitment [Line Items]
Amount of annual worldwide sales on which royalty is payable under condition two																				$ 150,000,000
Amount of annual worldwide sales on which royalty is payable under condition three																				300,000,000
Maximum [Member] | FOLOTYN [Member]
Long-term Purchase Commitment [Line Items]
Amount of annual worldwide sales on which royalty is payable under condition one																				150,000,000
Amount of annual worldwide sales on which royalty is payable under condition two																				$ 300,000,000
Maximum [Member] | Regulatory [Member]
Long-term Purchase Commitment [Line Items]
Milestone net sales achievement				$ 3,000,000
Milestone payments															$ 16,000,000													$ 16,000,000
Maximum [Member] | Commercial Progress And Sales Dependent [Member]
Long-term Purchase Commitment [Line Items]
Milestone payments															$ 107,000,000													107,000,000
INDIA | ZEVALIN [Member] | Licensing Agreements [Member]
Long-term Purchase Commitment [Line Items]
Potential milestone achievement			$ 1,500,000																		$ 1,500,000							$ 1,500,000
Percentage of royalty																												20.00%
License agreement contractual terms													15 years
Up-front non-refundable payment												$ 500,000
Recognition period for upfront payment																												10 years
Potential payment																												$ 3,000,000
Payment on regulatory milestones			1,500,000																		1,500,000							1,500,000
Allergan [Member]
Long-term Purchase Commitment [Line Items]
Up-front non-refundable payment																			$ 41,500,000
License fee																			$ 300,000
Allergan [Member] | Common Class A
Long-term Purchase Commitment [Line Items]
Common stock issued (shares) | shares							25,000
Stock issued							$ 100,000
Nippon Kayaku [Member]
Long-term Purchase Commitment [Line Items]
Upfront fee																		$ 15,000,000
Payment related to agreement																												10,000,000
Payment on achievement of commercialization milestones																												126,000,000
TopoTarget [Member]
Long-term Purchase Commitment [Line Items]
Potential milestone achievement			190,000,000																		190,000,000							$ 190,000,000
Upfront fee																	$ 30,000,000
Percentage of development cost																												70.00%
Percentage of development cost that is funded by TopoTarget for joint development plan																												30.00%
Additional payments based on the achievement of certain development														$ 10,000,000
Aggregate payout value																									$ 17,800,000
Second milestone payment																															$ 25,000,000
Payment on regulatory milestones			$ 88,000,000																		$ 88,000,000							$ 88,000,000
Principal executive office [Member] | Nevada [Member]
Long-term Purchase Commitment [Line Items]
Facility lease, non-cancelable operating lease expiring date																												Apr. 30, 2019
Research and development facility [Member] | California [Member]
Long-term Purchase Commitment [Line Items]
Facility lease, non-cancelable operating lease expiring date																												May 31, 2019

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Benefit for income taxes	$ 1,466	$ 464	$ 1,412	$ 635
U.S. federal statutory tax rate			35.00%
Tax on currency transactions	$ 2,000	$ 300	$ 2,000	$ 900
Accounting Standards Update 2016-09 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deferred income tax asset					$ 2,700
Excess tax benefit					$ 2,700

Stockholders' Equity (Detail)

Stockholders' Equity (Detail) - USD ($)	1 Months Ended				2 Months Ended	6 Months Ended	9 Months Ended
	Aug. 31, 2017	Jul. 31, 2017	Jun. 30, 2016	Dec. 31, 2015	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Class of Stock [Line Items]
Maximum proceeds	$ 150,000,000			$ 100,000,000
No. of Common Shares Issued (shares)		3,243,882			9,314,250	10,890,915
Proceeds from issuance of common stock		$ 23,745,000			$ 90,221,000	$ 73,869,000	$ 113,966,000	$ 73,869,000
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Outstanding (shares)			20
Issued in conversion (shares)			40,000
Dividends in arrears			$ 6,000

Subsequent Event (Detail)

Subsequent Event (Detail) - USD ($) $ in Thousands	Oct. 12, 2017	Oct. 31, 2017	Jul. 31, 2017	Dec. 31, 2016	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016	Oct. 13, 2017
Subsequent Event [Line Items]
Common stock, shares issued (shares)				80,466,735	94,061,740		94,061,740
Proceeds from issuance of common stock			$ 23,745		$ 90,221	$ 73,869	$ 113,966	$ 73,869
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock, shares issued (shares)		1,000,000
Proceeds from issuance of common stock		$ 14,300
2.75% Convertible Senior Notes Due 2018 [Member]
Subsequent Event [Line Items]
Number of instruments				9,963
Repurchase of principal				$ 10,000
Proceeds from unwinding				$ 21
2.75% Convertible Senior Notes Due 2018 [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Number of instruments	69,472
Repurchase of principal	$ 69,500
Repayments	27,300
Repayments, issuance of stock (shares)	5,400
Debt instrument face value									$ 40,600
Proceeds from unwinding	$ 5,800